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ABSTRACT 
 BACKGROUND: There has been an increase in the diagnosis of depression and 
the use of antidepressants, especially in women of childbearing age, in the past decade. 
This has drawn attention to the potential impact of depression and antidepressants on 
pregnancy and fetal development. 
OBJECTIVE: (i) To determine the impact of prenatal exposure to antidepressant 
on the risk of adverse birth outcomes. (ii) To assess the effect of type of antidepressants 
on the risk of adverse birth outcomes using selective serotonin reuptake inhibitors as the 
referent group. (iii) To assess the effect of duration and time of prenatal exposure to 
antidepressants on the risk of adverse birth outcomes.  
METHODS: The study was conducted using a population-based cohort including 
all singletons deliveries in years 2008 to 2014 in SC Medicaid population. Information on 
antidepressant medication and diagnosis of depression and birth outcomes were obtained 
from South Carolina Medicaid database and birth certificates. The exposed group 
comprised children of mothers who had a diagnosis of depression and used 
antidepressants at any time during their pregnancy. The reference group comprised 
children of mothers who had a diagnosis of depression but did not use any 
antidepressants during pregnancy. We estimated the association using Logistic 
Regression and Marginal Structural Models.  
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RESULTS: Approximately 107, 683 women had a diagnosis of depression in the SC 
Medicaid population. After applying the study inclusion and exclusion criteria, we got the 
study sample of 4,450 women. And approximately 36% women received antidepressants 
during pregnancy. (i) In our study we found that using logistic regression the odds of 
having preterm delivery were 1.58 (95%CI: 1.19 – 2.10) in those who received an 
antidepressant during pregnancy as compared to those who did not receive any 
antidepressants at any time during the pregnancy. Using marginal structural models, the 
odds of preterm delivery were 1.72 times (95% CI: 1.63 – 1.79) in the group that received 
antidepressants during pregnancy as compared to those who did not. Using logistic 
regression it was estimated that antidepressant use during pregnancy was associated with 
higher odds of the infant having low birth weight/being small for gestational age, OR = 
1.57 (95% CI: 1.42 – 2.76) and/or NICU admissions, OR: 1.45 (95%CI 1.28 – 2.26). 
Marginal structural models showed that the prenatal exposure to antidepressants 
increased the odd of having low birth weight/small for gestational age 1.63 times 
(95%CI: 1.53 – 1.73) and the odds of having a NICU admission by 1.66 times (95% CI: 
1.58 – 1.73). (ii) Upon comparing the different classes of antidepressants to SSRIs we 
found that the risk of adverse birth outcomes was not significantly different between the 
different types of antidepressants. Only TCAs had a statistically lower risk of NICU 
admissions as compared to SSRIs. Using marginal structural models we found that the 
risk of NICU admissions was 0.85 times (95% CI: 0.65 – 0.97) lower in TCAs as 
compared to SSRIs. (iii) Exposure to antidepressants in all three trimesters was 
associated with the risk of adverse birth outcomes. Although the duration of exposure that 
is the number of days for which the antidepressant was prescribed in each trimester was 
vii 
 
not associated with the risk of adverse birth outcomes. Conducting additional analysis we 
found that the risk of low birth weight/small for gestational age and NICU admissions 
was higher with exposure in the third and second trimester as compared to the first 
trimester. 
CONCLUSION: In conclusion we found that prenatal exposure to antidepressants 
is significantly associated with a higher risk of adverse birth outcomes such as preterm 
delivery, low birth weight/small for gestational age, and NICU admissions, irrespective 
of the type of antidepressant prescribed and duration and trimester of exposure. 
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CHAPTER 1 
INTRODUCTION 
1.1 DEPRESSION 
 
Depression is a mood disorder that causes a persistent feeling of sadness and loss 
of interest
1
. Symptoms of depression can be categorized in three groups—mood, 
cognitive, and physical symptoms. Mood symptoms include depressed, sad, or irritable 
mood; loss of interest in usual activities; inability to experience pleasure; feelings of guilt 
or worthlessness; and thoughts of death or suicide
1
. Cognitive symptoms include inability 
to concentrate and difficulty in making decisions
1
. Physical symptoms include fatigue, 
lack of energy, feeling either restless or slow, and changes in sleep, appetite, and activity 
levels
1
. World Health Organization (WHO) recognizes depression as a worldwide 
epidemic, with 5 percent of the global population suffering from the condition
2
. 
According to Centers for Disease Control and Prevention (CDC) depression is one of the 
leading causes of disability in the United States
3
. Depression statistics published by the 
CDC show that about 9 percent of adult Americans have feelings of hopelessness, 
despondency, and/or guilt that generate a diagnosis of depression
3
. At any given time, 
about 3 percent of adults have major depression, also known as major depressive 
disorder, a long-lasting and severe form of depression
3
. The average age for a person to 
be diagnosed with depression is 32
3
. The prevalence of depression is comparatively lower  
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(6.8%) among those age 65 and older
3
.  Prevalence of depression is also affected by race, 
according to the CDC, African-Americans have the highest rate of current depression 
(12.8 percent), followed by Hispanics (11.4 percent), and whites (7.9 percent)
 3
. A report 
published by National Institute of Mental Health (NIMH) states that women are 70 
percent more likely than men to experience depression during the course of their 
lifetimes
4
.
 
One in four women suffer symptoms of depression at some point during their 
life
5
. Women of childbearing age are at a higher risk for depression
2-4
. According to the 
American Congress of Obstetricians and Gynecologists (ACOG) between 14 – 23% of 
women struggle with symptoms of depression during pregnancy
6
.   
The personal and societal costs of depression are significant. They include higher 
rates of death, serious complications for chronic disease patients, significantly higher 
health care costs for employers, added family caregiver burden and associated substance 
abuse problems. Studies show that depression is associated with higher mortality rates in 
all age groups. In the United States, the total economic burden of depression was 
estimated to be US$ 83.1 billion in 2000, of which US$ 26.1 billion (31%) were direct 
medical costs, US$ 5.4 billion (7%) were suicide-related mortality costs and US$ 51.5 
billion (62%) were workplace costs
6
. Since then the societal cost of depression has 
increased to $118 billion in 2013
3-4
.  According to WHO, major depression carries the 
heaviest burden of disability among mental and behavioral disorders. It accounts for 3.7 
percent of all U.S. disability-adjusted life years (DALYs); and, 8.3 percent of all U.S. 
years lived with disability (YLDs) 
2, 4
.  
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1.2 ANTIDEPRESSANTS   
 
The most common treatments for depression are medication and psychotherapy. 
Based on their mechanism of action antidepressants are classified into the following 
therapeutic categories –  
 Selective serotonin reuptake inhibitors (SSRIs)   
 Serotonin-norepinephrine reuptake inhibitors (SNRIs) 
 Tricyclic antidepressants (TCAs) 
 Monoamine oxidase inhibitors (MAOIs) 
 Atypical agents 
Antidepressants were one of the 10 most popular type of drug dispensed in US in 
2013, with $13.7 billion in sales. According to the National Centre for Health Statistics 
(NCHS) antidepressants were the third most common prescription drugs taken by 
Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44 
years
7
. More than 60% of Americans taking antidepressant medication have taken it for 2 
years or longer, with 14% having taken the medication for 10 years or more
7
.  The CDC 
and NCHS also report that females are two and half times as likely to take antidepressant 
medication as males
2, 7
.   
1.3 DEPRESSION AND ANTIDEPRESSANTS IN PREGNANT WOMEN 
 
In 2005 the prevalence of major depression in pregnant women ranged from 3.1% 
– 4.9%, and that of major or minor depressive episodes ranged from 8.5% – 11% (minor 
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depression here refers to sub-threshold depression or depressive disorder not otherwise 
specified) 
8
. Since 2005 the prevalence of depression has increased
9
. According to the 
American Congress of Obstetrics and Gynecologists the prevalence of depressive 
disorders (major and minor depression) in pregnant women ranges from 14% to 23%
9-11
.  
The increase in prevalence of depression has translated to an increase in the use of 
antidepressants. Over the past decade the proportion of pregnancies with antidepressant 
use has increased from 5.7% of pregnancies to 13.4% of pregnancies and is projected to 
increase further 
6, 12
. Prevalence of antidepressant prescription is lower during pregnancy 
as compared to pre-pregnancy and post-partum
13
.  The use of antidepressants during 
pregnancy is mostly during the first trimester
13-14
. Studies show that there is a reduction 
in the use of antidepressants from the first trimester (3.7%) to the second (1.6%) to the 
third (1.1%)
 12-14
.  
1.3.1 South Carolina Medicaid Population 
 
According to CDC the current rate of depression in South Carolina is 9.6%
3
. 
According to a report published by the University of South Carolina in the year 2009 a 
total of 31,542 female Medicaid recipients had paid claims associated with a primary 
diagnosis of depression or 3.4 percent of the total Medicaid recipient population
15
. Total 
medical expenditures for this population were $390,062,477 accounting for 9.03 percent 
of the state Medicaid expenditures
15
.  Another report by the South Carolina Department 
of Health and Environment Control (DHEC) in the years 2004-2009 approximately 40% 
of pregnant of women had a diagnosis of depression in South Carolina Medicaid 
population
16
. Nearly 42% are prescribed antidepressants during pregnancy
16
.  
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1.4 IMPACT OF MATERNAL DEPRESSION AND PRENATAL EXPOSURE TO 
ANTIDEPRESSANTS ON BIRTH OUTCOMES 
  
Depression during pregnancy has received little attention from healthcare 
professionals and researchers as compared to postpartum mental health of women
16
, 
mainly due to the belief that pregnancy can have a protective effect against depression
17
. 
This has resulted in limited knowledge about depression during pregnancy and its impact 
on fetal growth and development
17
. However, there has been an increase in the diagnosis 
of depression and the use of antidepressants
18
, especially in women of childbearing age
18-
20
, in the past decade. This has drawn attention to the potential impact of depression and 
antidepressants on pregnancy and fetal development. 
Due to the unusual risk-benefit situation, healthcare providers avoid prescribing 
drugs during pregnancy
11
. However, studies show that maternal depression can have an 
impact on the pregnancy and fetus
21
. Untreated depression has been found to be 
associated with preterm delivery, low birth weight and small for gestational age
22-23
. 
Although no studies have explored the direct association between maternal depression 
and structural malformations, some researchers have found that maternal depression is 
associated with poor fetal and head growth
23
, providing evidence that depression may be 
associated with malformations as well.  
A number of studies have explored the association between prenatal exposure to 
antidepressants and poor birth outcomes. Many of the studies show that exposure to 
antidepressants during gestation is associated with preterm delivery, low birth weight, 
small for gestational age, and structural malformations
24-26
. Discontinuing the prescribed 
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antidepressants can lead to relapse. Approximately 68% of women who stopped taking 
antidepressants relapsed during pregnancy making the fetus susceptible to the harmful 
effects of depression
27
.  
Maternal depression and antidepressants both have been associated with adverse 
birth outcomes such as pre-term delivery, low birth weight/ small for gestational age and 
structural malformations
22-26
, which makes it difficult to study the independent 
association between antidepressants and adverse birth outcomes.  
1.5 BIOLOGICAL PLAUSIBILITY 
1.5.1 Maternal Depression 
 
Depression can have a direct effect on the development of fetus and maintenance 
of pregnancy
11
. It has been associated mainly with preterm delivery, low birth weight, 
and spontaneous abortion
11, 14, 28
. Very few studies have looked at the impact of maternal 
depression on structural malformations. Although the exact pathology of the phenomenon 
has not been identified there are two widely accepted theories. The first theory proposes 
that the neurobiological substrates of depression such as glucocorticoids have the ability 
to cross the placenta and can result in hormonal shifts and interactions, which in turn are 
detrimental to development of fetus and maintenance of pregnancy
29
. The second theory 
proposes that the fetus may be affected due to the altered fetal environment caused by 
maternal depression and stress
28, 29
.  Levels of hormones such as gonadal, estrogens and 
progesterone increase during pregnancy. Production of other hormones such as placental 
corticotropin-releasing hormone (CRH), cortisol, human chorionic gonadotropin, 
prolactin, b-endorphin, and thyroid hormone-binding globulin also increases during 
pregnancy. The production of these hormones is controlled by complex interactions and 
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feedback systems that exist between the hypothalamicpituitary-ovarian (HPO) axis and 
the hypothalamicpituitary-adrenal (HPA) axis. The HPA axis plays a vital role, as it’s 
functioning and release of hormones is influenced by pregnancy and by stress
29
. Studies 
show that women’s cortisol levels are higher when they experience negative moods30; 
providing evidence to support a link between the HPA axis and psychological distress 
during pregnancy
29, 30
. Changes in the HPA axis and subsequent changes in cortisol levels 
resulting from stress and/or depression can alter the fetal environment.  
Depression can also have an indirect impact on the fetus through poor health 
behaviors, such as poor eating and poor weight gain, and poor sleep and subsequent use 
of over the-counter medication, alcohol, tobacco, or caffeine
26
. 
1.5.2 Antidepressants  
 
  The potential impact of maternal depression on the development of fetus and 
maintenance of pregnancy has highlighted the risks of untreated depression; this in turn 
has contributed to an increased use of antidepressants during pregnancy. Unfortunately 
prenatal exposure to antidepressants can also result in adverse birth outcomes.  
Antidepressants can enter the fetal circulation by crossing the placenta
31
. The fetus may 
also be exposed to the drug through amniotic fluid, which means exposure to even greater 
amounts than usually considered 
31
. Although the biological mechanism is still unclear 
this exposure has been associated with adverse birth outcomes such as small for 
gestational age/low birth weight 
32,33
, preterm delivery
34-36
, and structural 
malformations
37-38
.   
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1.6 ADVERSE BIRTH OUTCOMES  
 
1.6.1 Preterm Delivery  
 
World Health Organization defines preterm delivery as delivery before 37 weeks 
of gestation are completed
39
. Every year, an estimated 15 million babies are born preterm. 
In 2013 it preterm birth complications were the leading cause of death among children 
under 5 years of age, responsible for nearly 1 million deaths
39
. A report published by 
National Center for Health Statistics stated that the rate of preterm birth in the US is 
12.7% 
40
. Preterm-related is the leading cause of infant deaths accounting for almost 
35%
41
. Preterm birth is also a leading cause of long-term neurological disabilities in 
children. Preterm birth costs the U.S. health care system more than $26 billion in 2005
41
. 
The preterm birth rate varies by race and ethnicity
42
. In 2012, 16.53 percent of babies 
born to non-Hispanic Black women were born preterm, compared to 10.29 percent of 
babies born to non-Hispanic White women, and 10.15 percent of babies born to 
Asian/Pacific Islander women. Among babies born to Hispanic women, 11.58 percent 
were born preterm, while the same was true for 13.25 percent of babies born to American 
Indian/Alaska Native women 
42-43
. Rates of preterm birth vary in different regions of the 
United States and among states
44
. Preterm birth rates are highest in Mississippi, Alabama, 
Louisiana, Kentucky, South Carolina, and the District of Columbia and lowest in New 
Hampshire, Vermont, Oregon, Minnesota, Alaska, Connecticut, and Idaho
45
. According 
to the March of Dimes the rate of preterm delivery in South Carolina was 13.8%
43
.  
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There are several factors associated with the risk of preterm delivery. Women 
who have delivered preterm before, or who have experienced preterm labor before, are 
considered to be at high risk for preterm labor and birth
46
. Multiple gestations or the use 
of assisted reproductive technology is associated with a higher risk of preterm labor and 
birth. One study showed that more than 50% of twin births occurred preterm, compared 
with only 10% of births of single infants
47
. Certain medical conditions such as urinary 
tract infection, diabetes, sexually transmitted diseases have also been associated with 
preterm delivery
48
.   Preterm labor and birth occur more often among certain racial and 
ethnic groups. Infants of African American mothers are 50% more likely to be born 
preterm than are infants of white mothers
49
. Age is also associated with the risk of 
preterm delivery. Women younger than age 18 are more likely to have a preterm 
delivery
47
. Women older than age 35 are also at risk of having preterm infants because 
they are more likely to have other conditions (such as high blood pressure and diabetes) 
that can cause complications requiring preterm delivery
49
. Other risk factors associated 
with preterm delivery are certain lifestyle and environmental factors, which include late 
or no health care during pregnancy, smoking, drinking alcohol, using illegal drugs, 
domestic violence, including physical, sexual, or emotional abuse, lack of social support, 
stress, long working hours with long periods of standing and exposure to certain 
environmental pollutants 
48
.  
Studies show that stress and depression are associated with a higher risk of 
preterm delivery
 48-50
. Some studies also show that the prevalence of preterm delivery is 
higher in mothers who take antidepressants during pregnancy as compared to those who 
do not
24-26, 33-34
. Although other studies have concluded that there is no significant 
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association between exposure to antidepressants during gestation and the odds of having 
preterm delivery
35-38
.   
1.6.2 Low Birth Weight/ Small for Gestational Age 
 
Low birth weight (LBW) infant is defined as the one whose weight is less than 
2,500 g (5 pounds 8 ounces) regardless of gestational age 
40
. Prevalence of low birth 
weight in the US is about 8% 
40
. Small for gestational age (SGA) babies are those who 
are smaller in size than normal for the gestational age, most commonly defined as a 
weight below the 10th percentile for the gestational age 
51-52
. According to the Centers for 
Disease Control and Prevention the prevalence of small for gestational age has been on 
the rise since 2005 and is currently about 11% 
53
. The LBW/SGA rate in South Carolina 
has risen from 9.3% to 10.1%, from 1993 to 2013
 54-55
. The risk of LBW/SGA is 
significantly greater among African Americans, whose rate is 14.6%, compared with 
7.6% of White or Hispanic babies
54-55
. The excess cost to the medical system of 
supporting a low or very LBW/SGA baby is high. An LBW/SGA baby incurs an average 
of $16,500 in hospital costs and a very low birth weight baby an average of $95,000 
54
. 
The total medical cost of LBW/SGA babies in South Carolina is over $160 million per 
year 
55
.  
There are several risk factors associated with LBW/SGA. Preterm labor is often a 
cause of LBW/SGA. Certain health conditions such high blood pressure, diabetes and 
infections may lead to LBW/SGA
46. Women who don’t gain enough weight during 
pregnancy are more likely to have a LBW/SGA baby than women who gain the right 
amount of weight. Smoking, drinking alcohol, and illicit drug use has also been 
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associated with LBW/SGA. Pregnant women who smoke are nearly twice as likely to 
have a LBW/SGA baby as women who don’t smoke49. Women younger than 17 years or 
older than 35 years are more likely to give birth to a LBW/SGA baby
49
. And 
race/ethnicity is a risk factor as well. In the United States, African-American women are 
more likely than others to have a LBW/SGA baby. Approximately 13% African-
American babies are born with LBW/SGA each year. 8.4 percent of Asian babies, 7.6 
percent of Native American babies, and about 7 percent of Hispanic and Non-Hispanic 
White babies are born with LBW/SGA
53-55
.   
Studies suggest that depression is an important risk factor for LBW/SGA
56
. 
Women with depression during pregnancy are at increased risk for LBW/SGA
57
. These 
studies stress the need for treating antenatal depression to reduce the risk of LBW/SGA. 
However, literature is conflicted regarding the association between gestational exposure 
to antidepressants and low birth weight/small for gestational age. Some studies show that 
prenatal exposure to antidepressants is associated with a higher risk of LBW/SGA
33-34
 
whereas other studies show that the association is minimal to none
35-38
.  
1.6.3 NICU Admissions 
 
Preterm and/or low birth weight infants need special care, including additional 
attention to breastfeeding and breast-milk feeding and to keeping them warm at home and 
in health facilities. Those with preterm birth complications, including respiratory 
problems, need appropriate treatment in hospitals. A neonatal intensive-care unit (NICU), 
also known as an intensive care nursery (ICN), is an intensive-care unit specializing in 
the care of ill or premature newborn infants
58-59
. Newborns, including those who are full 
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term and of normal birth weight, are admitted to a NICU for many types of illness. Every 
newborn admitted to a NICU experiences the benefits of such highly specialized care and 
is exposed to the associated risks and high costs. Despite the published research into 
interventions or patterns of care for specific populations, there has been no published 
study examining NICU admission rates across the entire range of newborn morbidity 
because the necessary data have, until recently, been unavailable or difficult to access
58-
59
.  
Neonatal intensive care (NICU) admissions increased from 2007 to 2012. In 
2012, there were 43.0 NICU admissions per 1000 normal-birth-weight infants (2500-
3999 g), while the admission rate for very low-birth-weight infants (<1500 g) was 844.1 
per 1000 live births
60
. Overall, admission rates during the 6-year study period increased 
from 64.0 to 77.9 per 1000 live births (relative rate, 1.22; 95% CI, 1.21-1.22 [P < .001]). 
Admission rates increased for all birth weight categories. Trends in relative rates adjusted 
for maternal and newborn characteristics showed a similar 23% increase (95% CI, 1.22-
1.23 [P < .001]). During the study period, newborns admitted to a NICU were larger and 
less premature, although no consistent trend was seen in weight for gestational age or the 
use of assisted ventilation
60-61
.  
Maternal depression and antidepressants have been associated with NICU 
admissions. Studies show that stress and depression are associated with a higher risk of 
NICU admissions
 62-64
. Some studies also show that the prevalence of NICU admissions 
are higher in infants born to mothers who take antidepressants during pregnancy as 
compared to those who do not
64-70
. Although other studies have concluded that there is no 
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significant association between exposure to antidepressants during gestation and the odds 
of NICU admissions
71-74
.   
1.7 SUMMARY  
A study conducted about perinatal depression in 2005 showed the prevalence of 
major depression in pregnant women is in the range of 3.1%–4.9%, and that of major or 
minor depressive episodes is in the range of 8.5%–11% (minor depression here refers to 
sub-threshold depression or depressive disorder not otherwise specified)
1-2
. Since 2005 
the prevalence of depression has increased. According to a recent report published by 
American Congress of Obstetrics and Gynecologists (2014) the prevalence of depressive 
disorders (major and minor depression) in pregnant women ranges from 14% to 23%3-4. 
The prevalence for major depression has reached up to 7.5%
2-4
.  This increase in 
prevalence of depression has directly translated to an increase in the use of 
antidepressants. Over the past decade the proportion of pregnancies with antidepressant 
use has increased from 5.7% to 13.4% and is projected to increase further 
5-6
. Both 
untreated depression and antidepressants have been associated with poor birth outcomes 
such as preterm delivery, low birth weight and small for gestational age
22-26
. There are a 
variety of other risk factors that have been associated with poor birth outcomes, these 
include maternal smoking, poor prenatal care, drinking alcohol, using illegal drugs, 
domestic violence etc
48-50,61
.  Maternal depression, in addition to all these risk factors 
makes assessing the impact of antidepressants alone on the fetus is a challenging 
22-23
.  
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CHAPTER 2 
LITERATURE REVIEW 
Depression is a growing concern to healthcare professionals. It is a mental illness 
that can be debilitating to patients and costly and challenging to treat. According to 
Center of Disease Control and Prevention an estimated 1 in 10 US adults suffer from 
depression
1
. Women are 70% more likely to suffer depression than men
1
.  Depression has 
become a common problem during and after pregnancy. Prevalence of depressive 
disorders in pregnant women ranges from 14% to 23%
2-3
.  
Depression if left untreated during pregnancy can negatively impact the mother 
and fetus/child. The suffering mothers are most likely to experience inadequate weight 
gain during pregnancy
4
, abuse substances
5
 and be at an increased risk of preeclampsia
6-8
. 
Untreated depression can also be associated with preterm delivery, increased risk for low 
birth weight infants
9-10
, fetal distress, increased risk of neonatal intensive care unit 
admissions and need for caesarian delivery
10-12
. Hence it is important to treat maternal 
depression during pregnancy, although only 13% of the women diagnosed with 
depression get treatment during pregnancy
13
. This might be related to the adverse 
outcomes associated with the use of antidepressants during pregnancy. Studies show that 
prenatal exposure to antidepressants is associated with preterm births, low birth 
weight/small for gestational age, structural malformations and increased risk of
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 admissions to the neonatal intensive care unit
14-20
, autism spectrum disorders and 
other neurodevelopmental disorders
22-23
.  
Over the past decade several studies have assessed the association between 
prenatal exposure to antidepressants and adverse birth outcomes, although the results 
have been inconsistent.  
2.1 PRETERM BIRTH 
A number of studies have examined the incidence of preterm birth in women 
prescribed antidepressants during pregnancy.  Most of these studies are observational 
studies. In most of the studies researchers have looked at the prevalence of preterm birth 
but in contrast, some studies looked at mean gestational age.  
Simon et al (2002)
26
, Djulus et al (2006)
27
, Oberlander et al (2006)
28
, Kallen et al 
(2004)
29
, Suri et al (2007)
30
, and Wisner et al (2009)
31
 have conducted studies that show 
that the odds of having preterm delivery are higher when there is exposure to 
antidepressants during gestation. On the other hand Sivojelezova et al (2004)
32
, Malm et 
al (2005)
33
, Andersson et al (2004)
34
 and Yonkers et al (2009)
35
 have concluded that there 
is no significant association between exposure to antidepressants during gestation and the 
odds of having preterm delivery. Studies that have found an association between in utero 
antidepressant exposure and gestational age typically show a small difference in mean 
gestation duration of about a week or less 
32-33,36
. The study conducted by Einarson et al 
(2003)
24
 showed that the association is dependent on the duration of exposure; that longer 
exposures are more likely to decrease gestational age
36
. All of these are prospective 
cohort studies, involving different classes of antidepressants (SSRIs, Mirtazapine, TCA 
and SNRI). Maschi et al (2008) revealed a correlation between preterm birth and chronic 
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exposure to antidepressants but not with short term exposure
57
. All of these studies have 
similar weaknesses, with no measures of actual drug exposure or controls for 
confounders such as smoking and in particular the effects of underlying depression.  
Some studies have tried to control for untreated maternal depression. Oberlander 
et al (2006)
36
 examined 119 547 prescription records matched with hospital separation 
records and found that SSRI-exposed babies had a higher rate of preterm birth than 
babies exposed to depression alone (p < 0.01). A further study, by the same group, of 
3500 cases found that increased length of drug exposure was related to higher risk of low 
gestational age and low birth weight (Oberlander et al 2008)
28
. These studies are 
weakened by the fact that hospital records may be unreliable and that the authors did not 
correct for multiple comparisons. A small prospective study compared women with 
depression alone and treatment with SSRIs and found a statistically significant higher 
preterm birth rate in the exposed infants (14% exposed group, 0% depressed group)
28
. In 
contrast, another small study did not detect any difference between treated and depressed 
groups 
32
. Wisner et al (2009) designed study a looked that looked at five overlapping 
groups using a prospective design
31
. Patients were classified into those with no SSRI or 
depression exposure, those with continuous or partial SSRI exposure and those with 
continuous or partial depression exposure. Unlike most other studies, exposure was 
confirmed with serum SSRI levels. The group with continuous SSRI exposure had a 
significantly higher preterm delivery rate with a RR of 5.43 (95%CI 1.98-14.84). The 
group with continuous depression also had a higher rate but this was no longer 
statistically significant when controlled for maternal age and race, RR 3.7 (95%CI 0.98-
14.13). The partial SSRI and partial depression groups were no different from controls.  
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Another study conducted by Simon et al (2002)
26
 evaluated the effects of prenatal 
antidepressant exposure on adverse perinatal outcomes using a matched case control 
study. The authors found that exposure to SSRIs were associated with a 0.9-week 
decrease in mean gestational age and a 175-g decrease in mean birth weight. The odds of 
having an adverse birth outcome was 4.3 (95%CI 1.5-12.2) times higher in the SSRI 
exposed group as compared to the non-exposed group. They also looked at TCA 
exposure and found that it was not significantly associated with adverse birth outcomes. 
In this study the authors used a within a group-model health maintenance organization, 
all infants  with apparent prenatal exposure to TCA or SSRI antidepressants were 
frequency matched to an unexposed comparison group by year of birth, maternal age, and 
mother’s lifetime use of antidepressant drugs and mental health care. A structured blind 
review of mothers’ and infants’ medical records examined perinatal outcomes. The 
authors also concluded that the effects on gestational age and birth weight were not 
limited to the infants exposed late in pregnancy. A similar finding was reported by 
Pastuszak et al. (1999) and Ericson et al. (18), while Chambers et al. (1996) found that 
only third-trimester fluoxetine exposure was associated with a greater risk of premature 
delivery.  On the other hand Suri et al (2004)
30
 conducted a cohort study by following 90 
women in a prospective, naturalistic design through pregnancy with monthly assessments 
of symptoms of depression and anxiety using the Structured Clinical Interview for DSM-
IV mood module for depression, the Hamilton Depression Rating Scale, the Beck 
Depression Inventory, and the Perceived Stress Scale. Participants included 49 women 
with major depressive disorder who were treated with antidepressants during pregnancy 
(group 1), 22 women with major depressive disorder who were either not treated with 
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antidepressants or had limited exposure to them during pregnancy (group 2), and 19 
healthy comparison subjects (group 3). The primary outcome variables were the infants' 
gestational age at birth, birth weight, 1- and 5-minute Apgar scores, and admission to the 
special care nursery. Groups 1, 2, and 3 differed significantly in gestational age at birth 
(38.5 weeks, 39.4 weeks, 39.7 weeks, respectively), rates of preterm birth (14.3%, 0%, 
5.3%, respectively), and rates of admission to the special care nursery (21%, 9%, 0%, 
respectively). Birth weight and Apgar scores did not differ significantly between groups. 
Mild to moderate depression during pregnancy did not affect outcome measures. They 
concluded that prenatal antidepressant use was associated with lower gestational age at 
birth and an increased risk of preterm birth but not with low birth weight or being small 
for gestational age. This study is limited by its small sample size. The authors looked at 
the impact of only one antidepressant that is Fluoxetine and did not account for the dose 
of the drug.   
A retrospective cohort study conducted by Pearson et al (2007)
32
 had a similar 
conclusion that no evidence of major increases in risk of preterm birth or other adverse 
neonatal outcomes following prenatal exposure to antidepressants, nor between SRIs and 
TCAs. They compared the medical records of 84 pregnant women with major depressive 
or anxiety disorders (DSM-IV criteria) who took antidepressants during pregnancy 
(cases) versus a 2:1 age- and parity-matched control group of 168 unexposed women. 
Women in the case group had sought psychiatric consultation regarding the use of 
medication from the Perinatal and Reproductive Psychiatry Program at the Massachusetts 
General Hospital between 1996 and 2000. There were no significant differences among 
cases versus controls and their offspring, with respect to various neonatal and obstetrical 
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outcomes, including gestational age and weight, although 1-minute Apgar scores were 
slightly lower in exposed infants. Admissions to the special care nursery were more 
frequent, but briefer and based on relatively minor indications, among case newborns. 
There were no significant differences in neonatal outcomes between exposures to 
serotonin reuptake inhibitor (SRI) and tricyclic (TCA) antidepressants. Although the 
authors of this study controlled for maternal depression they failed to mention the 
trimester of exposure and doses. Also, the sample size of this study is not large enough to 
give statistically significant results.  
2.1.1 Summary 
Preterm birth is a major clinical problem throughout the world. Numerous studies, 
of varying size and quality, have examined the effects of antidepressant medication use 
on pregnancy outcomes, including preterm birth. They differ in terms of the timing of the 
antidepressant exposure during pregnancy and adjustment for potential confounding 
variables, including lifestyle factors, co-morbidities, and the severity of the underlying 
depression. Although substantial, the literature is limited by inconsistent results and the 
lack of an appropriate control group. The majority of studies have used depressed women 
who are not on antidepressants or women with no depression and no antidepressant 
prescription as the control group. In both the cases the controls do not help clarify the 
impact of antidepressants. Also most of the studies have examined prenatal exposure to 
SSRIs, there is limited information about the other classes of antidepressants
24
. Another 
concern with the current literature is inadequate controlling of confounding. A number of 
studies have failed to control for confounders such as maternal smoking
24-25
, parity
8,11,24, 
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duration and time of exposure
13,18,25 
to antidepressants and most importantly maternal 
depression2
4-25
. 
2.2 LOW BIRTH WEIGHT and SMALL FOR GESTATIONAL AGE 
As with pre-term delivery the literature regarding the association between prenatal 
exposure to antidepressants and risk of low birth weight/small for gestational age 
(LBW/SGA) has conflicting results (Table 2). Studies conducted by Oberlander et al 
(2006)
20
, Simon et al (2002)
19
, and Wen et al (2006)
38
 found an association between 
gestational exposure to antidepressants and low birth weight/small for gestational age. 
They found that prenatal exposure to antidepressants increased the odds of the infant 
being low birth weight/ small for gestational age. Although the difference in the odds 
ratio in the exposed and unexposed group was minimal, this could be a result of the small 
sample size of these studies. Similar studies conducted by Djulus et al (2006)
19
, 
Sivojelezova et al (2004)
29
, Chun-Fai-Chan et al (2005)
39
 concluded that there is no 
association between gestational exposure to antidepressants and low birth weight/small 
for gestational age.  
A prospective cohort study conducted by Casper et al (2003) compared children 
whose mothers were diagnosed with major depressive disorder in pregnancy and elected 
not to take medication (n = 13) to children of depressed mothers treated with SSRIs (n = 
31) in terms of birth outcomes. The prevalence of preterm birth in the exposed group was 
found to be 3% as compared to 8% in the non-exposed group (p = 0.53). The mean birth 
weight of the infants in the exposed group was only 50g lesser as compared to the non-
exposed group (p =0.84). Although the authors mention that the healthy lifestyle of the 
women in the study (eg, use of prenatal vitamins, no smoking, little alcohol use, and 
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regular exercise) makes this sample different from that of other published pregnancy 
outcome studies and might have contributed to the finding that antidepressant drugs did 
not increase the risk of prematurity or low birth weight. Laine et al (2003) and Wisner et 
al (2009)  for confounders such as depression, smoking, maternal age or maternal weight, 
and these showed no differences in birth weight in babies born to exposed or non-
exposed mothers
34,44
. Although the relatively smaller sample size does not give the study 
sufficient statistical power to detect the differences exposed and unexposed groups in all 
of these studies.  
A similar study conducted by Kallen et al (2004) used data of 997 infants (987 
mothers) after maternal use of antidepressants based on prospectively recorded 
information in antenatal care documents. The study concluded that prenatal exposure to 
antidepressants increases the risk of LBW/SGA (OR 1.88 95%CI 1.28-2.26).  Wen et al 
(2006) conducted a retrospective cohort study of 972 pregnant women who had been 
given at least 1 antidepressant prescription in the year before delivery and 3878 pregnant 
women who did not any antidepressant and who were matched by the year of the infant's 
birth, the type of institute at birth, and the mother's postal code from 1990 to 2000 in the 
Canadian province of Saskatchewan. The study showed that the risks of low birth weight 
(adjusted odds ratio, 1.58; 95% CI, 1.19, 2.11were increased in infants who were born to 
mothers who had received antidepressants during pregnancy. A prospective case control 
study conducted by Oberlander et al (2008)
28
 showed similar results. The authors used a 
population-based maternal and neonatal health records that were linked to prenatal 
maternal prescription records for an antidepressant medication (n=3500). After 
controlling for maternal illness and duration of exposure, using propensity score 
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matching the study found that longer prenatal exposure increased the risks of lower birth 
weight (P<0.05).  
On the other hand Casper et al (2003) conducted a prospective cohort study where 
children whose mothers were diagnosed with major depressive disorder in pregnancy and 
elected not to take medication (n = 13) were compared 
with children of depressed mothers treated with SSRIs (n = 31) on birth outcomes. After 
the analysis the authors concluded that prenatal exposure antidepressants had no 
significant impact on the birth weight of the newborn. Suri et al (2004)
30
 followed sixty-
four outpatient women with an Axis I diagnosis of major depressive disorder or no 
psychiatric history were followed in each trimester of pregnancy with administration of 
the CES-D. A subset of the women with depression received treatment with fluoxetine 
during pregnancy. Subjects with a CES-D score greater than 16 at any time point were 
further assessed for the presence of an active major or minor depressive episode. The 
study had analyzable data for 62 women. No significant differences were found in 
outcome variables between those women with exposure to medication and/or prenatal 
depressed mood and those women without a history of depression.  Another study 
conducted by Djulus et al (2006)
27
 used a prospective cohort study with 2 comparison 
groups: disease-matched pregnant women diagnosed with depression taking other 
antidepressants and pregnant women exposed to non-teratogens. The primary outcome 
was major malformations in neonates; secondary endpoints included spontaneous 
abortions, therapeutic abortions, gestational age at birth, and mean birth weight. Women 
were recruited from 5 teratogen information services in Toronto, Canada; Farmington, 
Conn., U.S.A.; Jerusalem, Israel; Rome, Italy; Sydney, Australia; and from the Drug 
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Safety Research Unit in Southampton, United Kingdom. Women were recruited into the 
study from June 2002 to August 2005.  The authors found no difference in the mean 
weight of the infants in the exposed and unexposed groups.  
2.2.1 Summary 
A large number of studies have looked at the association between prenatal 
exposure to antidepressants and an increased risk of being low birth weight/small for 
gestational age. All of these studies are observational with varying study designs and 
conflicting results. Although the impact of maternal depression and stress on fetal 
development has been well documented
32-35
, many studies fail to control for maternal 
depression in either design or analysis. In addition a number of studies have failed to 
control for confounders such as maternal smoking
24-25
, parity
8,11,24, 
duration and time of 
exposure
13,18,25 
to antidepressants.  
2.3 NICU ADMISSIONS 
Several studies have analyzed the associate between neonatal outcomes and 
antidepressant exposure during pregnancy. Most of these studies show some association 
between gestational exposure to antidepressants and neonatal adaptation difficulties. 
Neonatal adaptation is measured in various ways, from gross markers such as NICU 
admission to more subtle evaluations such as behavioral observations, in different studies 
making it difficult to draw general conclusions. Large database or registry studies have 
variously suggested an increased 1.5 times increased risk of NICU admission with third 
trimester exposure compared to first trimester exposure 
38
, and increased risks of 
respiratory distress and low 
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APGAR scores 
49
.  
The 2005 meta-analysis
50
 of prospective controlled trials included consideration 
of 1066 mother – infant pairs and found a three-fold increased risk of SCN/NICU 
admission. None of the trials in the meta-analysis included a depressed, non-drug-treated 
group. Two subsequent studies do include such a group. Of these, Ferreira et al (2007) 
found a significant (p < 0.001) increase in abnormal movements, tone and respiratory 
symptoms in 76 infants exposed to SSRIs or venlafaxine in the third trimester
51
. 
Sivojelezova et al (2005) found that 132 infants exposed to citalopram in pregnancy had a 
four-fold increased incidence of NICU admission compared to matched infants exposed 
to untreated maternal depression or controls
32
. Whereas two other controlled studies did 
not find an association between antidepressant exposure and neonatal adaptation 
difficulties. Of these Casper et al (2003) was limited by a small sample size. Maschi et al 
(2008) on the other hand was a larger trial including 200 women treated with 
antidepressants and 1200 controls. Although a major limitation of this study was that the 
information was collected through an interview with the mothers, so data may not be 
accurate and an underreporting of neonatal complications, especially of the mild ones, is 
likely.  Studies examining the neonatal effects of antenatal exposure to TCAs are limited 
to case reports and case series. Several case reports describe an association between 
gestational clomipramine
48-49
and imipramine
50-52
 exposures with signs of neonatal 
adaptation difficulties. In a prospective case series
53
 of 18 pregnant women on TCAs 
(predominantly imipramine), all nine with third trimester exposure had infants with 
adaptation difficulties. With regard to the newer antidepressants, evidence is scant. Some 
of the controlled trials include venlafaxine exposure
54-56
 and suggest similar neonatal 
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adaptation difficulties to SSRIs. Mirtazapine features only in case reports
57-58
 and in one 
controlled study
56
, with a suggestion of both respiratory and thermoregulatory problems. 
One case report exists for duloxetine
59
 documenting neonatal adaptation symptoms.  
2.3.1 Summary 
The literature on association between prenatal exposure to antidepressants and an 
increased risk of NICU admission is limited as compared to the evidence on preterm 
delivery and low birth weight/small for gestational age. One reason for NICU admissions 
are not considered an outcome of interest is because they lack specificity. NICU 
admissions can sometimes be a result of poor birth outcomes like preterm delivery, small 
for gestational age or structural malformations. Studies that have examined the 
association between prenatal exposure to antidepressants and an increased risk of NICU 
admission have also been observational with varying study designs and conflicting 
results. These studies have failed to control for confounders such as maternal smoking
24-
25
, parity
8,11,24, 
duration and time of exposure
13,18,25 
to antidepressants and maternal 
depression
24-25
.  
2.4 GAPS IN THE LITERATURE 
The current literature related to the risk of adverse birth outcomes following 
prenatal exposure to antidepressants is dominated by information on SSRIs and to a 
lesser extent, TCAs and venlafaxine. Many of the published reports have contradictory 
results with regard to a possible association. These conflicting results are most probably 
the result of differences in the study cohorts and variation in the power the power of the 
study due to the sample size which plays a vital role in aiding to detect differences in rare 
events. Registry studies have been helpful in the sense that they provide information on 
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large numbers of participants, but they often rely on secondary data about prescriptions 
being filled and cannot confirm that antidepressants were actually taken.  
The main limitation of the existing literature are: 
2.4.1 Lack of Controlling for Maternal Depression  
Studies show that maternal depression can have an impact on the pregnancy and 
fetus
60
. Untreated depression has been found to be associated with preterm delivery, low 
birth weight and small for gestational age
60-61.
 Depression can have a direct effect on the 
development of fetus and maintenance of pregnancy
63
. It has been associated mainly with 
preterm delivery, low birth weight, and NICU admissions
64-66
. A majority of the studies 
in the currently literature do not control for maternal depression
68-70
.  
2.4.2 Inadequate controlling for confounders  
Several of the studies examining the impact of prenatal exposure to 
antidepressants on adverse birth outcomes fail to control for confounders such as 
smoking status, mother’s BMI, gestational diabetes, gestation hypertension, duration and 
trimester of exposure to antidepressants etc
68-70
. Also majority of studies do not control 
details about antidepressants such a duration and trimester of exposure.  
2.4.3 Large focus on SSRIs  
Since SSRIs are the most commonly prescribed antidepressants, a majority of the 
studies focus on the impact of prenatal exposure to SSRIs alone on adverse birth 
outcomes
68-70
. Although there is still information available about the impact of prenatal 
exposure to TCAs, the information related to Atypical and SNRIs is scant
33,45-47
.  
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2.4.4 Observational studies 
All the studies conducted to examine the association between prenatal exposure to 
antidepressants and risk of adverse birth outcomes have been observational. Several 
standard methods have been used in this setting to estimate the association between 
prenatal exposure to antidepressants and the risk of adverse birth outcomes
33-35,68-70
. 
However, none of the methods can be used to establish causality. Ideally a randomized 
controlled trial would be conducted to establish a causal association. Due to ethical 
concerns we cannot randomize treatment in this study population. 
2.5 SUMMARY 
Literature on the association between prenatal exposure antidepressants and risk 
of adverse birth outcomes though voluminous, is conflicting. Assessing the impact of 
antidepressants on birth outcomes is a challenging task. It is vital to delineate the effects 
of maternal depression, severity, other variables such as socioeconomic status, substance 
use, and comorbidity medical and mental illnesses, from the effect of antidepressants on 
birth outcomes
3, 14-16
. A systematic review of the relationship between antidepressant use 
and poor birth outcomes conducted by Udechuku et al (2010) showed that most studies 
do not have adequate power to detect rare events, and the large database analyses are 
limited by the lack of appropriate controls
47
. Another systematic review of literature 
concluded that although statistically significant associations between prenatal 
antidepressant exposure and adverse birth outcomes are identified, the group differences 
are small making it difficult to establish clinical significance
48
. Also most studies fail to 
properly define the exposure, such as specific antidepressant used, indication, dosage, 
time and duration of use, and number of antidepressants prescribed
48
. 
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All the studies in the current literature are observational studies; ideally, for 
estimation of the causal effects of prenatal exposure to antidepressants on adverse birth 
outcome we would need to conduct a randomized controlled trial. A large sample of 
women should be randomized to different treatment regimens at enrollment, with perfect 
adherence ensured and no censoring; here, the assumption of no confounding would be 
reasonable
48
. However, this is not possible in our study since withholding treatment 
would be unethical. Hence establishing a causal association between prenatal exposure to 
antidepressants and risk of adverse birth outcomes is not possible.  
2.6 AIMS and HYPOTHESIS 
Assessing the impact of antidepressants on the fetus is a challenging task as 
potential confounding factors must be considered. It is vital to distinguish the effects of 
maternal depression, socioeconomic status, maternal smoking, and comorbidities on birth 
outcomes from the impact of antidepressants on those same outcomes 
22-23
. Although 
substantial, the literature is limited by inconsistent results and the lack of an appropriate 
control group. The majority of studies have used depressed women who are not on 
antidepressants or women with no depression and no antidepressant prescription. In both 
cases the controls do not help clarify the impact of antidepressants. Also, while most of 
the studies have examined prenatal exposure to SSRIs, there is limited information about 
the other classes of antidepressants
24
. Another concern with the current literature is 
inadequate controlling of confounding. A number of studies have failed to control 
oconfounders such as maternal smoking 
24-25
, parity 
8,11,24
 , duration and time of exposure 
13,18,25
 to antidepressants and most importantly maternal depression 
24-25 
. The study 
proposes to fill these gaps in the literature by testing the following hypothesis.  
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Aim 1  
To explore the association between prenatal exposure to antidepressants and risk 
of adverse birth outcomes such as preterm delivery, low birth weight/small for gestational 
age, and NICU admissions.  
Study Hypothesis 1 
Depressed women exposed to antidepressants during pregnancy have a higher risk 
of adverse birth outcomes compared to women not exposed to antidepressants during 
pregnancy.  
Aim 2  
To determine the association between types of antidepressant used on the risk of 
adverse birth outcomes such as preterm delivery, low birth weight/small for gestational 
age and NICU admissions.  
Study Hypothesis 2 
The risk of having adverse birth outcomes is higher in women prescribed 
Selective Serotonin Reuptake Inhibitors compared to those depressed women who have 
been prescribed other types of antidepressants. 
 
 
Aim 3 
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To determine the effect of trimester and duration of antidepressants on the risk of 
adverse birth outcomes such as preterm delivery, low birth weight/small for gestational 
age and NICU admissions.  
Study Hypothesis 3 
Depressed women who have late pregnancy exposure and for a longer duration 
have greater risk of adverse birth outcomes compared to those with comparatively early 
pregnancy exposure and shorter duration. 
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CHAPTER 3 
METHODS 
3.1 DATA SOURCE  
Data used in this study came from 2 administrative sources: 1) South Carolina 
Medicaid claims 
1
, and 2) South Carolina registry of births from South Carolina 
Department of Health and Environmental Control (DHEC)
 2
. The South Carolina 
Revenue and Fiscal Affairs Office (RFA) created the de-identified dataset by merging 
South Carolina Medicaid claims with the birth certificates.  
3.1.1 South Carolina Medicaid Claims  
Medicaid is South Carolina’s aid program through which the federal and state 
governments provide insurance for eligible low-income adults, children, pregnant 
women, elderly adults and people with disabilities
 1-5
. The database contained information 
regarding an individual’s diagnosed medical conditions and the medications prescribed. 
Medical conditions were coded using the International Classification of Diseases, 9th 
revision, Clinical Modification (ICD-9-CM) codes. The pharmacy claims file of the 
dataset contained information regarding the prescribed medications coded using National 
Drug Codes (NDC), generic names and brand names 
1-5
. To address medication use as a 
depression treatment option in low-income pregnant women, we utilized South Carolina 
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Medicaid claims data to identify a patient population that would most closely represent 
our target population.  
3.1.2 South Carolina Birth Registry  
 The South Carolina DHEC maintains the South Carolina Registry of Births 
which is a database of all birth certificates issued in the state of South Carolina
5
. The 
database contained the following information: birth weight, gestational age, weight for 
gestational age, maternal height, maternal smoking, maternal alcohol use, maternal race, 
maternal and paternal occupation, conditions during the pregnancy (ex. gestational 
hypertension, anemia, eclampsia, gestational diabetes, uterine bleeding), birth 
abnormalities or anomalies (ex. cleft palate, heart malformations), multiple births, NICU 
admissions etc. Data from the birth certificates gave us information regarding the birth 
outcomes such as pre-term delivery, low birth weight/small for gestational age, and 
NICU admissions which helped us identify the cases accurately.  
3.2 SELECTION OF STUDY POPULATION  
The study population consisted of pregnant women who were enrolled in SC 
Medicaid between the years 2008 – 2014 and fulfilled the following inclusion and 
exclusion criteria.  
3.2.1 Inclusion Criteria  
 Pregnant women of age between 18 - 50 years  
 Pregnancy ending with a delivery (live birth or stillbirth)  
 Diagnosis of depression concurrent with pregnancy  
 Enrolled for Medicaid continuously for the entire pregnancy (SC Medicaid 
requires enrollment every month, and the database captures the claims filed 
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during the months enrolled. Hence to ensure that use antidepressants during the 
entire term of pregnancy is captured, it is important that the study participant be 
continuously enrolled in SC Medicaid during that time.) 
3.2.2 Exclusion Criteria  
 Multiple births  
 Illicit drug users (ICD 9 Code – 305.90)  
If a woman had more than one pregnancy between 2008 and 2014, then each 
pregnancy during which all eligibility criteria were fulfilled will be considered separately.  
3.3 EXPOSURE  
Pharmacy claims were used to identify all antidepressant prescriptions filled or 
refilled during the pregnancy and before delivery. Study participants with no 
antidepressant prescriptions during this period were considered unexposed. In this study 
the following antidepressants were considered (brand name listed in parentheses): 
 Selective serotonin reuptake inhibitors (SSRIs) – Fluoxetine (Prozac), 
Fluvoxamine (Luvox), Sertraline (Zoloft), Paroxetine (Paxil), Escitalopram 
(Lexapro), and Citalopram (Celexa).  
 Tricyclic antidepressants (TCAs) – Amitriptyline (Elavil), Clomipramine 
(Anafranil), Desipramine (Norpramin), Doxepin (Sinequan), Imipramine 
(Tofranil), Nortriptyline (Pamelor, Aventyl), Protriptyline (Vivactil), and 
Trimipramine (Surmontil).  
 Atypical antidepressant – Bupropion (Wellbutrin), Duloxetine (Cymbalta), 
Venlafaxine (Effexor), Mirtazapine (Remeron), and Trazodone (Desyrel). 
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 Serotonin-Norepinephrine Reuptake inhibitors (SNRIs) – Desvenlafaxine 
(Pristiq), Duloxetine (Cymbalta), Venlafaxine (Effexor), Venlafaxine XR 
(Effexor XR), Milnacipran (Savella), and Levomilnacipran (Fetzima).. 
For study participants who are prescribed more than one class of antidepressant 
during pregnancy both the classes were considered separately.  
3.3.1 Duration of gestational exposure  
The duration of gestational exposure was calculated as the number of days the mother 
had been prescribed the antidepressant in each trimester. To estimate the duration of 
exposure, we first estimated the date of conception based on the date of delivery and 
gestational age. It is known that 
10-13 
Gestational Age = Date of Delivery – Date of Conception 
Gestational age was obtained from the birth certificates, and date of delivery was 
estimated using the dates corresponding to the delivery procedure codes. Using the date 
of conception the time period for each trimester was calculated.  
1
st
 Trimester = Date of Conception + 90 days 
2
nd
 Trimester = Last date of 1
st
 trimester + 90 days 
3
rd
 Trimester = Last date of 2
nd
 trimester – Date of Delivery 
Based on the dates of the trimester and the dates of exposure, number of days 
antidepressant was prescribed during each trimester was calculated.  
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In case there was a change in prescribed antidepressant the antidepressant prescribed 
for the longer duration was the focus.   If duration was similar for both antidepressants, 
the first antidepressant prescribed was considered.  
3.4 OUTCOMES 
A study participant was considered to have the outcome if she had one or more of 
the following adverse birth outcomes:  
3.4.1 Preterm delivery  
Preterm delivery was defined as a delivery before completion of 37 weeks of 
gestation
14-18
. We got information on preterm delivery was obtained from birth 
certificates.  
3.4.2 Low birth weight  
Low birth weight was defined as birth-weight less than 2,500 g (5 pounds 8 
ounces) regardless of gestational age
17, 18-23
. We got information on preterm delivery was 
obtained from birth certificates.  
3.4.3 Small for gestational age  
Small gestational age was defined as birth-weight below the 10th percentile of the 
birth-weights for the gestational age in the given population
19-23
.   Indication that the 
infant was small for gestation age was provided in the birth certificate file. All births 
covered by SC Medicaid between years 2008-2014 served as the referent group
19
.  
Although low birth weight and small for gestational age are not the ideal 
measures for intrauterine growth, these are the two most commonly use measures in the 
literature. Studies have found misclassification low birth weight as it is associated with 
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preterm delivery and the magnitude and direction of misclassification differed by preterm 
and full term birth. Also small for gestational age may not have been calculated 
accurately as the estimation of gestational age is not always accurate
24-25
. 
3.4.4 Neonatal Intensive Care Unit Admissions  
NICU admission was identified from the birth certificates file. Information on 
whether the infant had to be admitted to NICU right after birth was recorded in the birth 
certificates 
24-28
.  
3.5 COVARIATES AND POTENTIAL CONFOUNDERS  
3.5.1 Mother’s Age  
Mother’s age was obtained from birth certificates files. For analysis age was 
categorized as:  
 18 – 28 years 
 29 – 38 years 
 ≥ 39 years 
3.5.2 Mother’s BMI  
Pre-pregnancy BMI of the mother was reported in the birth certificate and was 
categorized as: 
 Underweight (BMI < 18.5) 
 Normal weight (18.5 ≤ BMI > 25) 
 Overweight (25 ≤ BMI > 35) 
 Obese (BMI ≥ 35) 
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3.5.3 Mother’s Education  
Information regarding the education of the mother at the time of pregnancy was 
obtained from the birth certificate. It was categorized as: 
 Less than high school 
 High school or GED 
 High school + some college 
 Bachelor’s degree or more 
3.5.4 Kotelchuck Index/Prenatal Care 
The Kotelchuck Index, also called the Adequacy of Prenatal Care Utilization 
(APNCU) Index, is measure used to estimate adequacy of prenatal care a women 
received during pregnancy
19
. It is calculated using – (i) the date prenatal care began 
(initiation) and (ii) the number of prenatal visits between prenatal care initiation   and 
delivery (received services). The Kotelchuck index classifies the adequacy of initiation as 
follows: pregnancy months 1 and 2, months 3 and 4, months 5 and 6, and months 7 to 9, 
with the underlying assumption that the earlier prenatal care begins the better. To classify 
the adequacy of received services, the number of prenatal visits is compared to the 
expected number of visits for the period between initiation and delivery date. The 
expected number of visits is based on the American College of Obstetricians and 
Gynecologists prenatal care standards for uncomplicated pregnancies, and is adjusted for 
gestational age at date of care initiation, and for gestational age at delivery
19
. 
Kotelchuck Index was categorized as follows:  
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 Inadequate (< 50%) 
 Intermediate (50% to 79%) 
 Adequate (80% to 109%) 
 Adequate Plus (≥ 110%) 
3.5.5 Smoking Status  
Mother’s smoking status was reported in the birth certificate file. Smoking status was 
recorded for two time periods, (i) before pregnancy and (ii) during pregnancy. 
 During Pregnancy Smoking Status was categorized as:  
o Yes – smoked during pregnancy 
o No – did not smoke during pregnancy 
o Unknown 
 Pre-pregnancy Smoking Status was categorized as:  
o Yes – smoked before pregnancy 
o No – did not smoke before pregnancy 
o Unknown 
Although the number of cigarettes smoked per day was not reported.  
3.5.6 Diabetes 
Information regarding the diagnosis of diabetes for the mother was given in the birth 
certificate and the SC Medicaid medical claims file. The information on diabetes was 
recorded as:  
 Yes – having a diagnosis of diabetes 
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 No – not having a diagnosis of diabetes 
Diagnosis of diabetes was confirmed from the SC Medicaid medical files using ICD-9 
codes (648.8).   
3.5.7 Gestational Diabetes  
Information regarding the diagnosis of gestational diabetes for the mother was 
given in the birth certificate and the SC Medicaid medical claims file. The information on 
gestational diabetes was recorders in the birth certificates file as:  
 Yes – having a diagnosis of gestational diabetes 
 No – not having a diagnosis of gestational diabetes 
Diagnosis of gestational diabetes was confirmed from the SC Medicaid medical files 
using ICD-9 codes (648.8).  
3.5.8 Hypertension  
Information regarding the diagnosis of hypertension for the mother was given in the 
birth certificate and the SC Medicaid medical claims file.  
The information on gestational diabetes was recorders in the birth certificates file as:  
 Yes – having a diagnosis of hypertension 
 No – not having a diagnosis of hypertension 
Diagnosis of gestational diabetes was confirmed from the SC Medicaid medical files 
using ICD-9 codes (648.8).  
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3.5.9 Gestational Hypertension  
Information regarding the diagnosis of gestational hypertension for the mother was 
given in the birth certificate and the SC Medicaid medical claims file. 
The information on gestational hypertension was recorders in the birth certificates file as:  
 Yes – having a diagnosis of gestational hypertension  
 No – not having a diagnosis of gestational hypertension 
Diagnosis of gestational hypertension was confirmed from the SC Medicaid medical files 
using ICD-9 codes (642).  
3.5.10 Parity  
Parity was defined as the number of pregnancies that end /delivered after 20 weeks 
gestation.  The number of fetuses in a pregnancy does not change the parity. Information 
regarding parity was obtained from the birth certificates.  
3.5.11 Number of Risk Factors  
Total number of risk factors for poor birth outcomes present at the birth of an infant 
were recorded in the birth certificate. The risk factors included poor prenatal care, 
gestational diabetes, gestational hypertension, race, mother’s age, and mother’s BMI. As 
the number of risk factors present increase so does the risk of adverse birth outcome.  
3.5.12 Infant Sex  
Infant’s gender at the time of birth was obtained from the birth certificate file, 
specified as male and female.  
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3.5.13 Race  
As of 1990, Live Births are reported by race of mother instead of race of child
19
. Race 
was categorized as follows in the birth certificate files:  
 Non-Hispanic White 
 Non-Hispanic Blacks 
 Hispanics 
 Others 
3.5.13 Previous Poor Outcomes  
The birth certificates contained information regarding experience of adverse birth 
outcomes associated with a previous pregnancy. Adverse/poor birth outcomes included 
the following:  still born, pre-term delivery, low birth weight/small for gestational age, 
structural malformations, NICU admissions, and abortions/miscarriages.  The 
information was coded as follows: 
 Yes – had at least 1 of the adverse birth outcome in previous pregnancies 
 No – did not have any of the adverse birth outcomes in previous pregnancies  
3.6 STATISTICAL ANALYSIS 
Descriptive statistics (means, median, std. dev., percentages) was used to report 
and describe the population. Hypothesis testing for categorical variables was conducted 
using the Chi-square test.  Hypothesis testing for continuous variables was conducted 
using the t-test.  
Two statistical methods were used to test the three study hypotheses –  
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1. Logistic Regression  
2. Marginal Structural Models (MSM) 
There are several standard methods could be used to estimate the association between 
prenatal exposure to antidepressants and the risk of adverse birth outcomes. However, 
none of the methods can establish causality 
14-28
.  Ideally a randomized controlled trial 
should be conducted to establish a causal association between gestational exposure to 
antidepressants and an increased risk of adverse birth outcomes. Due to ethical concerns, 
we cannot randomize treatment in the study population. Hence we used Marginal 
Structural Models to estimate the causal effect of gestational exposure to antidepressants 
on risk of adverse birth outcomes
29-30
. MSMs are a new class of causal models used in 
epidemiology, the parameters of which are estimated through inverse-probability-of 
treatment weighting. MSMs provide more robust estimates, with narrower confidence 
intervals. In addition, a structural classification of bias distinguishes between biases 
resulting from conditioning on common effects (“selection bias”) and those resulting 
from the existence of common causes of exposure and outcome (“confounding”)30-34. 
However the use of MSM in reproductive epidemiology/perinatal epidemiology has 
been limited.   We used two statistical methods because marginal structural models help 
us delineate antidepressants from depression. Also, marginal structural models give us 
the tool to statistically mimic a randomized control trial. We used logistic regression   
like many previously published studies to make our results more comparable.     
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3.6.1 Method 1 – Logistic Regression  
A logistic regression was conducted to calculate the adjusted odds ratios along 
with 95% confidence intervals using unexposed study population as the referent group.  
Logit (Y) = β0 + β1L + β2A + β3x1 + β4x2 
Y = adverse birth outcomes (preterm delivery, low birth weight/small for gestational age 
and NICU admission) 
A= use of antidepressants (SSRIs/TCAs/SNRIs/Atypicals)  
L= maternal depression  
x1 , x2 , x3, …..= covariates such as mother’s age, mother’s weight, parity and other 
demographic variables etc  
Backward selection was used to identify the variables significant at p-value <0.05. 
In the analysis mother's age, mother's weight, mother's education, prenatal care 
(kotelchuck index), smoking status’, parity, number of risk factors, infant sex, mother’s 
race, year of birth, use of antidepressants, gestational diabetes, gestational hypertension, 
and previous poor birth outcomes were found to be significant.  
To ensure that the variables in the equation are not correlated with each other we 
checked for multicollinearity, and found that number of risk factors was correlated to 
gestational diabetes, gestational hypertension, and previous poor birth outcomes. Number 
of risk factors included all risk factor associated with the three outcomes such as 
infections, gestational diabetes, gestation hypertension, previous poor birth outcome etc. 
Therefore we retained only the number of risk factors and removed other collinear 
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variables. Multicollinearity can cause issues such as increase in variance of the 
coefficient estimates and make the estimates very sensitive to minor changes in the 
model, resulting in unstable and difficult to interpret coefficient estimates. (The 
correlation matrix of the final set of predictor variables is presented in Appendix A) 
3.6.2 Method 2 – Marginal Structural Models 
The model was fitted in a two stage process
30
:  
1. Each study participant’s probability of having their own treatment history was 
calculated and used to derive inverse-probability-of-treatment weights (IPTW) 
which were then standardized.  
2. The treatment–outcome association was estimated in a regression model that w 
weighted using the standardized IPTWs. 
The Directed Acyclic Graph represents the association between maternal depression 
(L), antidepressant (A) and adverse birth outcomes (Y)
30-32
. 
 
Y represents the adverse birth outcomes (preterm delivery, low birth weight/ small for 
gestational age, and structural malformations.) 
A represents the exposure to antidepressants (dichotomous) 
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Maternal depression L is a vector that predicts treatment A. ‘L’ accounts for all 
variables such as age, race, parity, and other demographics. It also accounts for dose 
and type of antidepressant.  
We first created a pseudo-population using Inverse Probability (IP) weighting 
where the arrow from the confounders L to the treatment A was removed. Here we 
assume that the vector L has all the confounders that can open a backdoor path from 
A to Y. Controlling for L will then eliminate all confounding in the pseudo-
population. That is, the association between A and Y in the pseudo-population 
consistently estimates the causal effect of A on Y. The pseudo-population was created 
by weighting each individual by the inverse of the conditional probability of receiving 
the treatment, which are defined as 
𝑊𝐴 = 1/𝑓(𝐴|𝐿) 
 
W
A – Inverse probability weight  
A – Exposure to antidepressants 
L – Maternal Depression 
The denominator ƒ (A|L) is the probability of getting the treatment conditional on the 
measured confounders given by 
𝑃𝑟[𝐴 = 1|𝐿] 
The probability of getting treatment given the individual has depression was 
[𝐴 = 1|𝐿] , and the probability that an individual does not get treatment given that she 
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has depression can be given by 𝑃𝑟[𝐴 = 0|𝐿]  . Although as treatment is dichotomous the 
following holds true  
𝑃𝑟[𝐴 = 0|𝐿] = 1 −  𝑃𝑟[𝐴 = 1|𝐿] 
Weights were stabilized using the stabilizing factor ƒ (A). The mean of the stabilized 
weights was 1, as the size of the pseudo population equals the size of the actual 
population. The stabilized weight is given by 
𝑆𝑊𝐴 = 𝑓(𝐴)/𝑓(𝐴|𝐿) 
SW
A – Standardized inverse probability weight  
The reason for using stabilized weights was that they are statistically superior to non-
stabilized weights and will give comparatively narrower 95% confidence intervals. To 
estimate 𝑃𝑟[𝐴 = 1|𝐿] for each strata of L we fitted a logistic regression model for the 
probability of having depression with all the covariates. Next estimated the casual 
difference 𝐸[𝑌𝑎=1] − 𝐸[𝑌𝑎=0] by fitting the mean model 𝐸[𝑌|𝐴] = 𝜃0 + 𝜃1𝐴 with 
individuals weighted by their estimated stabilized IP weights given by 𝑃?̂?[𝐴 = 1]/
𝑃?̂?[𝐴 = 1|𝐿] for the depressed population and (1 − 𝑃?̂?[𝐴 = 1])/(1 − 𝑃?̂?[𝐴 = 1|𝐿]) for 
those who are not depressed. Using this counterfactual contrast we build the following 
model  
𝐸[𝑌𝑎] = 𝛽0 + 𝛽1𝑎 
A = 1 – gestational exposure to antidepressants  
A = 0 – no gestational exposure to antidepressants 
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 𝑌𝑎=1 – Counterfactual outcome given everyone in the study population received 
antidepressants 
𝑌𝑎=0 – Counterfactual outcome given nobody in the study population received 
antidepressants 
The notations used to describe the model have been borrowed from Robins et al
30, 
35-36
.  
MSMs have been described and used by Hernan and Robins to estimate the causal 
effect of zidovudine on the survival of human immunodeficiency virus-positive men 
participating in the Multicenter AIDS Cohort Study
38
. The authors found MSMs to be a 
better suited model for causal inference as compared to standard statistical models. The 
assumptions of MSMs are the same as those in point exposure studies - accurate 
information, and no misspecification of the model 
37-38
.   
Although limited in number there are some perinatal epidemiology studies that 
have used MSM. For example MSM has been used to establish the causal effect of iron 
supplement use during pregnancy on odds of anemia at delivery in the presence of time-
dependent confounding 
34
. Data from pregnant women enrolled in the Iron 
Supplementation Study (Raleigh, North Carolina, 1997–1999) were used 34. The authors 
concluded that if a data set with rich information on confounders is available, MSMs can 
be used straightforwardly to make robust inferences about causal effects 
treatments/exposures in epidemiologic research 
34
.  
All statistical analysis will be conducted using Statistical Analysis Software 
version 9.4. Codes to conduct analysis using marginal structural models were taken from 
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the Causal Inference Book. (Hernán MA, Robins JM (2016). Causal Inference. Boca 
Raton: Chapman & Hall/CRC, forthcoming)
 30
.  
3.6.3 Testing Study Hypothesis 1 
 The risk of adverse birth outcomes such as preterm delivery, low birth 
weight/small for gestational age, and NICU admissions is higher in woman who received 
antidepressants during pregnancy as compared to those who did not take 
antidepressants. 
  A separate analysis was conducted for each adverse birth outcome – preterm 
delivery, low birth weight/small for gestational age and NICU admissions, controlling for 
all the available confounders. The analysis was conducted using logistic regression and 
marginal structural models. Adjusted odds ratio along with 95% confidence intervals 
were calculated for the association between antidepressant use during pregnancy and risk 
of each adverse birth outcomes. Pregnant women with a diagnosis of depression who did 
not have an antidepressant prescription were considered as the referent group. Mother’s 
age, parity, mother’s weight, kotelchuck index, total number of risk factors, and 
previously poor birth outcomes were found to be significant in the analysis.  
3.6.4 Testing Study Hypothesis 2 
 The risk of adverse birth outcomes such as preterm delivery, low birth 
weight/small for gestational age, and NICU admissions is higher in woman who received 
Selective Serotonin Reuptake Inhibitors (SSRIs) antidepressants during pregnancy as 
compared to other class of antidepressants such as Tricyclic Antidepressants (TCAs), 
Selective Norepinephrine Reuptake Inhibitors (SNRIs). 
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The second hypothesis was tested using the same methods. Each antidepressant type was 
compared to the unexposed group using logistic regression and marginal structural 
models. In addition we conducted another analysis using SSRIs as the reference group to 
compare the risk between different classes of antidepressants. Adjusted odds ratios along 
with 95% confidence intervals were calculated for the association between type of 
antidepressant use during pregnancy and risk of each adverse birth outcomes. Mother’s 
age, parity, mother’s weight, mother’s education, kotelchuck index, total number of risk 
factors, and previously poor birth outcomes were found to be significant in the analysis.  
3.6.4 Testing Study Hypothesis 3 
Depressed women who have antidepressants during the first trimester of 
pregnancy (early) and for a longer duration have greater risk of adverse birth outcomes 
compared to those with exposure in the third trimester of pregnancy (late) and for a 
shorter duration. 
A separate analysis was conducted for each adverse outcome comparing exposure to 
antidepressant during first, second and third trimester to test the third hypothesis. The 
analyses were conducting using logistic regression and marginal structural models, 
controlling for duration of exposure in each trimester. Adjusted odds ratio along with 
95% confidence intervals were calculated for the association between antidepressant use 
during pregnancy and risk of each adverse birth outcomes for 1
st
, 2
nd
 and 3
rd
 trimesters. 
Mother’s age, parity, mother’s weight, mother’s education, year of birth, total number of 
risk factors, and previously poor birth outcomes were found to be significant in the 
analysis. Also additional analysis was conducted with women who received 
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antidepressants only in Trimester 1 or 2 or 3, using women who got antidepressants only 
in the first trimester.  
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CHAPTER 4 
RESULTS 
Study population consisted of pregnant women with a diagnosis of depression, 
continuously enrolled in Medicaid for the entire term of their pregnancy, during the years 
2008 - 2014.  During the study period (2008-2014) a total of 411,003 births were 
financed by SC Medicaid. The prevalence of depression among pregnant women in the 
SC Medicaid population was 26.2% that is approximately 107,683 women had a 
diagnosis of depression before or during pregnancy. After applying the study inclusion 
and exclusion criteria, the study sample comprised of 4,450 women. Out of the 4,450 
women included in our analysis, 1,743 had multiple pregnancies during the study period. 
About half of these women (901) had two pregnancies during the study period, 549 had 
three pregnancies and 293 had more than three pregnancies during the study period. Each 
pregnancy had to fulfill the inclusion-exclusion criteria to be included in the study.   
Table 1 presents the demographic and clinical characteristics of the study 
population. A total of 1,641 women in the study population had received at least one 
antidepressant during their pregnancy and were categorized as exposed. All the others 
who did not receive any antidepressants during their pregnancy were categorized as 
unexposed.  
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The mean age of the study participants was relatively higher in the exposed group 
compared to the unexposed group (27.6 years vs 24.5 years, respectively). A large 
number of study participants fell in the age range of 18-28 years [unexposed – 2,250 
(80.1%); exposed 1,049 (63.9%)]. Proportion of women aged ≥39 years was smaller 
[unexposed: 27 (0.96%); exposed: 69 (4.2%)].  
Overall, in both exposed and unexposed the proportion of non-Hispanic whites 
was higher than that of non-Hispanic blacks, Hispanics and others. The proportion of 
non-Hispanic whites was higher in the exposed (71%) as compared to the unexposed 
group (60.2%), whereas the proportion of non-Hispanic blacks was relatively lower 
exposed group (25.8%) as compared to the unexposed group (37.1%). The proportion of 
Hispanics and other races was significantly lower in the both unexposed and exposed 
groups.  
BMI was obtained from the birth certificates that record the pre-pregnancy BMI 
of the mother. About half of the study population was either overweight (BMI ≥ 25 to < 
30) or obese (BMI of ≥ 30) [unexposed: 1,587 (56.5 %); exposed: 1,008 (61.2 %)]. These 
results were consistent with observations of other studies that looked at prevalence of 
obesity in women of the lower socioeconomic strata
1-3
.  About one-third of the study 
participants reported to have less than a high school education [unexposed: 1,170 (41.7 
%); exposed: 589 (35.9 %)], and very few had a bachelor’s or a higher degree 
[unexposed: 41 (1.5 %); exposed: 40 (2.4 %)].  
According to Kotelchuck Index reported on the birth certificates, the level of 
prenatal care was ‘adequate plus’ for more than 45% of the study population, whereas 
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about 25% were reported to have received ‘inadequate’ or ‘intermediate’ prenatal care. 
The distribution of population by the levels of prenatal care received was similar in the 
exposed and unexposed groups.  
In the study population the proportion of women smoking before pregnancy was 
higher than the proportion of women smoking during pregnancy, although the smoking 
status of a large majority of women was unknown for both before and after pregnancy.  
Also, the proportions of smokers and non-smokers for both before and during pregnancy 
were similar in the exposed and unexposed groups.  
The prevalence of gestational diabetes was relatively lower in the study 
population and did not differ significantly between the exposed and unexposed groups
4-5
. 
However the proportion of women affected by gestational hypertension is within the 
range projected by the Center of Disease Control (CDC), which is about 5% to 7%
6-7
. 
The prevalence of pre-pregnancy diabetes and pre-pregnancy hypertension is similar to 
the prevalence estimated for women below the age of 50 by CDC
8-10
.  
In about 33% of the women in both the exposed and unexposed group the 
pregnancy being considered in the study was their second pregnancy. The proportion of 
first pregnancies considered for study was lower in the exposed group (15.5%) as 
compared to the unexposed group (27.8%). Higher parity (≥ 3 children) was 
comparatively more prevalent in the exposed group (4.1%) compared to the unexposed 
group (2.5 %).  
The history of a poor birth outcomes such as pre-term delivery, low birth 
weight/small for gestational age, NICU admissions or structural malformations, was 
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relatively higher in the exposed group (16%) as compared to the unexposed group (12.7 
%).  
The distribution of infant gender was similar across exposed and unexposed 
groups, the proportion of females (~ 51%) was slightly higher than males (~ 48%). 
However, the distribution of infants born in exposed and unexposed groups was 
significantly different each year from 2008-2014. This corresponds with the trend of 
increase in the number of antidepressant prescribed during pregnancy from 2008-2014
11-
12
.  
Selective Serotonin Reuptake Inhibitors (SSRIs) were the most commonly 
prescribed antidepressants during pregnancy. A total of 1,152 (69%) of the study 
participants in the exposed group were prescribed SSRIs. Atypical Antidepressants were 
prescribed to 254 (15.5%), followed by Selective Norepinephrine Reuptake Inhibitors 
(SNRIs) prescribed to 171 (10.4%) and Tricyclic Antidepressants (TCAs) prescribed to 
83 (2.1%) study participants. (See Table 1)  
 Table 4.1 Demographic and Clinical Characteristic of Pregnant Women with a 
Diagnosis of Depression Enrolled in SC Medicaid during their entire term of 
Pregnancy 
Maternal/Infant 
Characteristics 
No 
Antidepressant 
Use During 
Pregnancy 
Antidepressants 
Prescribed During 
Pregnancy 
p-value 
N (%) N (%)   
Total  2809 (100%) 1641 (100%)   
Mother's Age (Years)        
    18 – 28  2250 (80.10%) 1049 (63.92%) <0.001 
    29 – 38   532 (18.94%) 523 (31.87%) <0.001 
    ≥ 39  27 (0.96%) 69 (4.20%) <0.001 
Mother's Weight        
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Maternal/Infant 
Characteristics 
No 
Antidepressant 
Use During 
Pregnancy 
Antidepressants 
Prescribed During 
Pregnancy 
p-value 
N (%) N (%)   
    Underweight 232 (7.62%) 105 (6.40%) <0.001 
    Normal 990 (35.24%) 528 (32.18%) <0.001 
    Overweight 654 (23.28%) 414 (25.23%) <0.001 
    Obese 933 (33.21%) 594 (36.20%) <0.001 
Mother's Education       
    Less than High School 1170 (41.65%) 589 (35.89%) <0.001 
    High School or GED 917 (32.65%) 560 (34.13%) <0.001 
    High School + Some 
College 
681 (24.24%) 452 (27.54%) <0.001 
    Bachelor's Degree or 
More 
41 (1.46%) 40 (2.44%) <0.001 
Prenatal Care 
(Kotelchuck Index)       
    Inadequate 611 (21.75%) 331 (20.17%) <0.001 
    Intermediate 214 (7.62%) 109 (6.64%) <0.001 
    Adequate 663 (23.60 %) 388 (23.64%) <0.001 
    Adequate Plus 1321 (47.03%) 813 (49.54%) <0.001 
Smoking Status       
    Pre-pregnancy 1117 (39.77%) 664 (40.46%) 0.05 
    During Pregnancy 981 (34.92%) 601 (36.62%) 0.05 
Diabetes       
    Pre-pregnancy 45 (1.60%) 46 (2.8%) 0.05 
    Gestational 137 (4.88%) 79 (4.81%) 0.05 
Hypertension       
    Pre-pregnancy 82 (2.92%) 61 (3.72%) <0.001 
    Gestational 163 (5.8 %) 82 (5 %) <0.001 
Parity       
    First 782 (27.8%) 254 (15.5 %) 0.05 
    Second  972 (34.6%) 536 (32.7%) 0.05 
    Third 606 (21.6%) 446 (27.2%) <0.001 
    More than Three 449 (16 %) 405 (24.7%) <0.001 
Number of Risk 
Factors        
    None 1514 (53.9%) 804 (49%) 0.166 
    One 959 (34.1%) 595 (36.3%) 0.166 
    Two 267 (9.5%) 175 (10.7%) 0.166 
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Maternal/Infant 
Characteristics 
No 
Antidepressant 
Use During 
Pregnancy 
Antidepressants 
Prescribed During 
Pregnancy 
p-value 
N (%) N (%)   
    Three or more 69 (2.5%) 67 (4.1%) 0.166 
Previous Poor 
Outcomes  
356 (12.7%) 262 (16%) 0.178 
Infant Sex       
    Male 1448 (51.6%) 852 (52%) <0.001 
    Female 1361 (48.5%) 789 (48.1%) <0.001 
Mother’s Race         
    Non-Hispanic White 1690 (60.2%) 1166 (71%) <0.001 
    Non-Hispanic Black 1043 (37.1%) 423 (25.8%) <0.001 
    Hispanic 60 (2.1%) 36 (2.2%) <0.001 
    Other 16 (0.6%) 16 (1%) <0.001 
Year of Birth       
    2008 444 (15.8%) 143 (8.7%) 0.431 
    2009 437 (15.6%) 176 (10.7%) 0.512 
    2010 427 (15.2%) 184 (11.2%) 0.223 
    2011 457 (16.3%) 233 (14.2%) 0.021 
    2012 426 (15.2%) 253 (15.4%) 0.021 
    2013 309 (11%) 311 (19%) 0.356 
    2014 309(11%) 341 (20.8%) 0.511 
Antidepressant Use        
    Selective Serotonin 
Reuptake Inhibitors  
N/A 1132 (69%) N/A 
    Atypical 
Antidepressants  
N/A 254 (15.5%) N/A 
    Serotonin–
norepinephrine Reuptake 
Inhibitor 
N/A 171 (10.4%) N/A 
    Tricyclic 
Antidepressants 
N/A 83 (5.1%) N/A 
Note: Risk Factors: poor pre-natal care; previous adverse birth outcomes; gestational 
diabetes, gestational hypertension, race, mother’s age, and mother’s BMI, previous 
poor birth outcomes, etc. Previous Poor Birth Outcomes: pre-term delivery; low birth 
weight/small for gestational age; structural malformations; NICU admissions.; N/A – 
Not applicable; NICU – Neonatal Intensive Care Unit  
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4.1 RESULTS FOR HYPOTHESIS 1 
 
Study Hypothesis 1: Depressed women exposed to antidepressants during 
pregnancy have a higher risk of adverse birth outcomes compared to women not exposed 
to antidepressants during pregnancy.   
The prevalence of adverse birth outcomes was higher in the exposed group 
compared to the unexposed group (See Table 2). The prevalence of preterm birth was 
17.25% in the exposed group versus 14.31% in the unexposed group (p-value < 0.01). 
The number of NICU admissions was also higher in the exposed group (8.23%) as 
compared to the unexposed group (7.62%) (p-value < 0.01). A similar pattern was 
observed in the low birth weight/small for gestational age infants; the proportion was 
found to be 17.25% in the exposed group whereas it was 16.59% in the unexposed group 
(p-value  < 0.01) (See Table 2).     
These differences in the proportion remained significant after controlling for 
various confounders such as mother’s age, mother’s education, parity, mother’s weight, 
mother’s race, mother’s smoking status during pregnancy and before pregnancy, 
gestational diabetes and hypertension, adequacy of prenatal care estimated using the 
Kotelchuck Index etc. A logistic regression was conducted for each outcome controlling 
for significant confounders.  In addition, another analysis was conducted using the 
marginal structural models to delineate the effect of antidepressants on the birth outcomes 
from the effect of maternal depression. Both the analysis yielded similar results (See 
Table 2).   
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The results for marginal structural models were similar to the results produced 
using logistic regression. The point estimates were slightly higher, showing stronger 
association and the confidence intervals were narrower (See Table 2).  
4.1.1 Prenatal Exposure to Antidepressants and the Risk of Preterm Delivery 
 
When conducting analysis using logistic regression the odds of having preterm 
delivery were 1.58 (95%CI: 1.19 – 2.10) times higher in the study participants that 
received an antidepressant during pregnancy as compared to those who did not receive 
any antidepressants at any time during the pregnancy.  
Whereas, according to the analysis conducted using marginal structural models, 
the odds of preterm delivery were 1.72 times (95% CI: 1.63 – 1.79) in the group that 
received antidepressants during pregnancy as compared to the group that did not receive 
an antidepressant during pregnancy.  
4.1.2 Prenatal Exposure to Antidepressants and the Risk of Low Birth Weight/Small 
for Gestational Age 
Using logistic regression it was estimated that antidepressant use during 
pregnancy was associated with higher odds of the infant having low birth weight/being 
small for gestational age- OR = 1.57 (95% CI: 1.42 – 2.76.) 
Similar result was observed when the analysis was conducted using marginal 
structural models. the odds of having low birth weight/being small for  gestational age 
were 1.63 times higher in the exposed group (95%CI: 1.53 – 1.73) as compared to the 
unexposed group. 
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4.1.3 Prenatal Exposure to Antidepressants and the Risk of NICU Admissions 
 
A similar pattern was observed in the probability of NICU admissions. According 
to the analysis conducted using logistic regression the odds of an infant being admitted to 
NICU were almost twice in the exposed group as compared to the unexposed group (OR: 
1.45; 95%CI 1.28 – 2.26).  
According to marginal structural models, the estimated probability of being 
admitted in NICU was 1.66 times higher with prenatal exposure to antidepressants than 
without (95% CI: 1.58 – 1.73).  
Table 4.2 Risk of having adverse birth outcomes between depressed pregnant women 
exposed to antidepressants during pregnancy and those who were not exposed to 
antidepressants during pregnancy 
Adverse Birth 
Outcomes 
No 
Antidepressant 
Use During 
Pregnancy 
N (%) 
Used 
Antidepres-
sants 
During 
Pregnancy  
N (%) 
Logistic 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model  
OR (95% CI) 
Pre-term 
Delivery  
402 (14.31%) 
283 
(17.25%) 
1.58  
(1.19 – 2.10) 
1.72  
(1.63 – 1.79) 
Low Birth 
Weight/ Small for 
Gestational Age 
466 (16.59%) 
283 
(17.25%) 
1.57  
(1.42 – 2.76) 
1.63  
(1.53 – 1.73) 
NICU Admission  
214 (7.62%) 135 (8.23%) 
1.45  
(1.28 – 2.26) 
1.66  
(1.58 – 1.73) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence 
Interval 
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4.1.4 Summary 
The prevalence of adverse birth outcomes was higher in the exposed group as 
compared to the unexposed group. Conducting a logistic regression controlling for all the 
confounders confirmed the association of the prenatal exposure to antidepressants and an 
increased risk of adverse birth outcomes. The odds of having an adverse birth outcome 
ranged from 1.45 (95%CI: 1.28 – 2.26) to 1.72 (95%CI: 1.63 – 1.79). Delineating the 
effect of antidepressants from depression using marginal structural models showed a 
stronger association and had narrower confidence intervals as compared to logistic 
regression.     
 
4.2 RESULTS FOR HYPOTHESIS 2 
 
Study Hypothesis 2: The risk of having adverse birth outcomes is higher in women 
prescribed Selective Serotonin Reuptake Inhibitors compared to those depressed women 
who have been prescribed other types of antidepressants. 
As previously discussed SSRIs were the most commonly prescribed 
antidepressants during pregnancy [1152 (68.99%)]. Atypical antidepressants and SNRIs 
were prescribed to relatively fewer study participants [254 (15.48%) and 171 (10.42%) 
respectively], TCAs were the least commonly prescribed antidepressants [83 (2.06%)].  
4.2.1 Risk of Preterm Delivery Associated with Type of Antidepressants Prescribe 
during Pregnancy 
The risk of having a preterm delivery was higher for all antidepressant classes 
when compared to the unexposed group. Analysis conducted using logistic regression 
showed that the odds of having a preterm delivery were 1.95 (95% CI: 1.32 – 2.66) times 
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higher in study participants that received SSRIs during pregnancy as compared to those 
who did not receive an antidepressant during pregnancy. Atypical antidepressant were 
associated with the 1.89 (95%CI: 1.23 – 2.69) times higher odds of having a preterm birth 
as compared to those who did not receive any antidepressants during pregnancy. SNRIs 
and TCAs showed a similar association. The odds of preterm birth 1.80 (95%CI: 1.23 – 
2.69) times higher in the SNRIs group, and 1.75 (95%CI: 1.32 – 2.89) times higher in the 
TCA group as compared to those who were not prescribed any antidepressant during 
pregnancy.  
Using marginal structural models a similar pattern was observed. The odds of 
having preterm delivery were 1.95 (95% CI: 1.71 – 2.15) times higher in the SSRIs 
group, 1.85 (95% CI: 1.45 – 2.11) times higher in the atypical antidepressants group, 1.75 
(95% CI: 1.47 – 2.00) times higher in the SNRIs group, and 1.81 (95% CI: 1.78 – 2.01) 
times higher in the TCAs group when each group was compared to those who did not 
receive any antidepressants during pregnancy.  
When a logistic regression was conducted using SSRIs as the referent group, we 
found that the odds of having preterm birth were not significantly associated with the 
class of antidepressants prescribed during pregnancy. Atypicals and SNRI groups were 
associated with 1.03 (95% CI: 0.67 – 1.54) times higher odds, and 0.95 (95% CI: 0.74 – 
1.82) times higher odds than the SSRIs group. However, these results were not significant 
as the odds are close to 1 and the confidence interval contains 1. Although not 
statistically significant, TCAs were associated with relatively lower odds of having a 
preterm delivery than SSRIs [OR: 0.89 (95% CI: 0.69 – 1.00)].  
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The group that was prescribed TCAs during pregnancy had lower odds of having 
preterm delivery as compared to those who were prescribed SSRIs during pregnancy 
[OR: 0.85 (95% CI: 0.65 – 0.97)]. Atypicals and SNRI groups were associated with 1.08 
(95% CI: 0.98 – 1.23) times higher odds, and 1.05 (95% CI: 0.85 – 1.19) times higher 
odds than the SSRIs group.  
Table 4.3 Comparison of Risk of Preterm Delivery between Types of Antidepressants 
Prescribed during Pregnancy  
Risk of Preterm Delivery associated with Class of Antidepressant Prescribed 
during Pregnancy  
  
Referent Group - Unexposed 
Referent Group - 
SSRIs 
 Class of 
Antidepre
-ssants 
Prescribed 
during 
Pregnancy 
# 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR (95% 
CI) 
SSRIs 933  
1.95  
(1.32 – 2.66) 
1.95  
(1.71 – 2.15) 
--- --- 
Atypicals  216 
1.89  
(1.23 – 2.69) 
1.85  
(1.45 – 2.11) 
1.03 
 (0.67 – 1.54) 
1.08  
(0.98 – 1.23) 
SNRIs  140 
1.80  
(1.21 – 2.03) 
1.75  
(1.47 – 2.00) 
0.95 
 (0.74 – 1.82) 
1.05  
(0.85 – 1.19) 
TCAs  68 
1.75   
(1.32 – 2.89) 
1.81  
(1.78 – 2.01) 
0.89  
 (0.69 – 1.00) 
0.85  
(0.65 – 0.97) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence 
Interval 
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4.2.2 Risk of Low Birth Weight/Small for Gestational Age Associated with Type of 
Antidepressants Prescribe during Pregnancy  
Analysis conducted using logistic regression showed that the odds of having a low 
birth weight/small for gestational age were 1.78 (95%CI: 1.45 – 2.78) times higher in 
study participants that received SSRIs during pregnancy as compared to those who did 
not receive an antidepressant during pregnancy. Atypical antidepressant were associated 
with the 1.65 (95% CI: 1.21 – 2.69) times higher odds of having a low birth weight/small 
for gestational age as compared to those who did not receive any antidepressants during 
pregnancy. SNRIs and TCAs showed a similar association. The odds of low birth 
weight/small for gestational age 1.69 (95% CI: 1.41 – 2.78) times higher in the SNRIs 
group, and 1.66 (95% CI: 1.25 – 2.12) times higher in the TCA group as compared to 
those who were not prescribed any antidepressant during pregnancy.  
Using marginal structural models a similar pattern was observed. The odds of 
having low birth weight/small for gestational age were 1.80 (95%CI: 1.52 – 1.97) times 
higher in the SSRIs group, 1.70 (95%CI: 1.32 – 1.86) times higher in the atypical 
antidepressants group, 1.73 (95%CI: 1.50 – 1.89) times higher in the SNRIs group, and 
1.71 (95%CI: 1.68 – 1.89) times higher in the TCAs group when each group was 
compared to those who did not receive any antidepressants during pregnancy.  
When a logistic regression was conducted using SSRIs as the referent group, we 
found that the odds of having low birth weight/small for gestational age were not 
significantly associated with the class of antidepressants prescribed during pregnancy. 
Atypicals and SNRI groups were associated with 1.06 (95% CI: 0.59 – 1.66) times higher 
odds, and 1.02(95% CI: 0.64 – 1.62) times higher odds than the SSRIs group. TCAs were 
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associated with relatively lower odds of having a low birth weight/small for gestational 
age than SSRIs [OR: 0.91 (95% CI: 0.68 – 1.10)]. The results were not statistically 
significant.  
According to the marginal structural models it was found that group that was 
prescribed TCAs during pregnancy had lower odds of having low birth weight/small for 
gestational age as compared to those who were prescribed SSRIs during pregnancy [OR: 
0.95 (95% CI: 0.89 – 1.05)]. Atypicals and SNRI groups were associated with 1.07 (95% 
CI: 0.75 – 1.14) times higher odds, and 1.05 (95% CI: 0.79 – 1.18) times higher odds 
than the SSRIs group. However, these results were not statistically significant.  
Table 4.4 Comparison of Risk of Low Birth Weight/Small for Gestational Age between 
Types of Antidepressants Prescribed during Pregnancy  
Risk of Risk of Low Birth Weight/Small for Gestational Age associated with 
Class of Antidepressant Prescribed during Pregnancy  
  
Referent Group - 
Unexposed 
Referent Group - SSRIs 
 Class of 
Antidepr-
essants 
Prescribed 
during 
Pregnancy 
# 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
SSRIs 935  
1.78  
(1.45 – 2.78) 
1.80  
(1.52 – 1.97) 
--- --- 
Atypicals  211 
1.65  
(1.21 – 2.56) 
1.70 
 (1.32 – 1.86) 
1.06  
(0.59 – 1.66) 
1.07  
(0.75 – 1.14) 
SNRIs  141 
1.69  
(1.41 – 2.78) 
1.73 
 (1.50 –1.89) 
1.02  
(0.64 – 1.62) 
1.05  
(0.79 – 1.18) 
TCAs 70 
1.66  
(1.75 – 2.12) 
1.71  
(1.68 – 1.89) 
0.91  
 (0.68 – 1.10) 
0.95  
(0.89 – 1.05) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence 
Interval 
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4.2.3 Risk of NICU Admissions Associated With Type of Antidepressants Prescribe 
during Pregnancy 
 
Analysis conducted using logistic regression showed that the odds of having a 
NICU admissions were 1.92 (95% CI: 1.41 – 2.54) times higher in study participants that 
received SSRIs during pregnancy as compared to those who did not receive an 
antidepressant during pregnancy. Atypical antidepressant were associated with the 1.71 
(95% CI: 1.32 – 2.76) times higher odds of having a NICU admissions as compared to 
those who did not receive any antidepressants during pregnancy. SNRIs and TCAs 
showed a similar association. The odds of NICU admissions 1.83 (95%CI: 1.33 – 2.75) 
times higher in the SNRIs group, and 1.75 (95% CI: 1.65 – 2.72) times higher in the TCA 
group as compared to those who were not prescribed any antidepressant during 
pregnancy.  
Using marginal structural models a similar pattern was observed. The odds of 
having NICU admissions were 1.80 (95%CI: 1.52 – 1.97) times higher in the SSRIs 
group, 1.80 (95% CI: 1.77 – 2.00) times higher in the atypical antidepressants group, 1.77 
(95% CI: 1.32 – 1.97) times higher in the SNRIs group, and 1.84 (95% CI: 1.39 – 1.99) 
times higher in the TCAs group when each group was compared to those who did not 
receive any antidepressants during pregnancy.  
When a logistic regression was conducted using SSRIs as the referent group, we 
found that the odds of having NICU admissions were not significantly associated with the 
class of antidepressants prescribed during pregnancy. Atypicals were associated with 1.04 
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(95% CI: 0.67 – 1.52) times higher odds than the SSRIs group. Whereas, TCAs and 
SNRI were associated with relatively lower odds of having a NICU admissions than 
SSRIs [OR: 0.89 (95% CI: 0.63 – 1.12); OR: 0.95 (95% CI: 0.85 – 1.10) respectively]. 
However, the results were not statistically significant.  
According to the marginal structural models it was found that group that was 
prescribed TCAs and SNRIs during pregnancy had lower odds of having NICU 
admissions  as compared to those who were prescribed SSRIs during pregnancy [OR: 
0.91 (95% CI: 0.87 – 1.09); OR: 0.98 (95% CI: 0.85 – 1.23) respectively]. Atypicals were 
associated with 1.06 (95% CI: 0.85 – 1.10) times higher odds than the SSRIs group. 
However, these results were not statistically significant.  
Table 4.5 Comparison of Risk of NICU Admissions between Types of Antidepressants 
Prescribed during Pregnancy  
Risk of NICU Admissions associated with Class of Antidepressant Prescribed 
during Pregnancy  
  
Referent Group - Unexposed 
Referent Group - 
SSRIs 
 Class of 
Antidepres
-sants 
Prescribed 
during 
Pregnancy 
# 
Logistics 
Regression OR 
(95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
SSRIs 95  
1.92  
(1.41 – 2.54) 
1.89  
(1.77 – 2.00) 
--- --- 
Atypicals  16 
1.71  
(1.32 – 2.76) 
1.80  
(1.32 – 1.97) 
1.04   
(0.67 – 1.52) 
1.06  
(0.85 – 1.10) 
SNRIs  15 
1.83  
(1.33 – 2.75) 
1.84  
(1.39 – 1.99) 
0.95  
(0.85 – 1.10) 
0.98  
(0.85 – 1.23) 
TCAs 9 
1.75  
(1.65 – 2.72) 
1.79  
(1.67 – 1.96) 
0.89   
(0.63 – 1.12) 
0.91  
(0.87 – 1.09) 
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Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence 
Interval 
 
4.2.4 Summary 
 
When each class of antidepressant was independently compared to the unexposed 
group, it was found that all the classes of antidepressants were associated with a higher 
risk of adverse birth outcomes. Both logistic regression and marginal structural models 
yielded similar results. Upon comparing the different classes of antidepressants to SSRIs 
we found that the risk of adverse birth outcomes was not significantly different between 
the different types of antidepressants. Only TCAs had a statistically lower risk of NICU 
admissions as compared to SSRIs. Using marginal structural models we found that the 
risk of NICU admissions was 0.85 times (95% CI: 0.65 – 0.97) lower in TCAs as 
compared to SSRIs. These results are can attributed to a variety of reasons, TCA were 
prescribed to relatively fewer people as compared to the other antidepressants. Also, 
TCAs prescription has reduced over the past decade and is mostly prescribed to older 
women. Mother’s of age above 40 are more likely to have poor birth outcomes; this 
might dilute the association of TCAs and risk of adverse birth outcomes.  
4.3 RESULTS FOR HYPOTHESIS 3 
 
Hypothesis 3: Depressed women who have late pregnancy exposure and for a 
longer duration have greater risk of adverse birth outcomes compared to those with 
comparatively early pregnancy exposure and shorter duration.  
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A majority of the study participants received antidepressants during the third 
trimester of their pregnancy 781, followed by the second trimester 620, and only 158 
study participants received antidepressants during the first trimester.  
4.3.1 Prenatal Exposure to Antidepressants in the First Trimester of Pregnancy and 
Risk of Preterm Delivery 
 
 According to the analysis conducted using logistic regression it was found that the 
odds of having preterm delivery were 1.98 times higher (95%CI: 1.2 – 2.1) in the group 
that was exposed to antidepressants during the first trimester of pregnancy as compared 
to women who did not receive any antidepressants during the first trimester. Duration of 
exposure was not significantly associated with the risk of preterm term delivery (OR: 
1.07 95%CI: 0.84 – 1.37).  
Similar results were observed when the analysis was conducted using marginal 
structural models. The odds of having a preterm delivery were 1.8 times (95% CI: 1.5 – 
2.1) higher in women who received an antidepressant during the first trimester of 
pregnancy as compared to those who did not receive any antidepressants during the first 
trimester of pregnancy. Duration of exposure was not significantly associated with the 
risk of preterm term delivery in the first trimester (OR: 1.13 95%CI: 0.94 – 1.28).  
4.3.2 Prenatal Exposure to Antidepressants in the First Trimester of Pregnancy and 
Risk of Low Birth Weight/Small for Gestational Age 
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Using logistic regression is was estimated that the probability of having low birth 
weight/small for gestational age infants was 1.99 (95%CI: 1.9 – 2.4) times higher in the 
group exposed to antidepressants during the first trimester of pregnancy as compared to 
those who did not receive an antidepressant during the first trimester of pregnancy. Each 
unit increase in the duration of exposure in the first trimester was associated with 1.19 
times higher odds of having low birth weight/small for gestational age (95%CI 0.95 – 
1.48), although the association was not statistically significant.  
According to marginal structural models, the odds of having low birth 
weight/small for gestational age were 1.95 times higher (95%CI 1.6- 2.2) in the group 
receiving antidepressants during the first trimester of pregnancy as compared to the group 
which did not receive any antidepressants during first trimester of  pregnancy. A unit 
increase in the duration of exposure to antidepressants was not significantly associated 
with the risk of low birth weight/small for gestational age (OR: 1.21 95%CI: 0.97 – 1.28). 
4.3.3 Prenatal Exposure to Antidepressants in the First Trimester of Pregnancy and 
Risk of NICU Admission 
 
According to logistic regression  the risk of NICU admissions was estimated to be 
1.8 (95%CI: 1.5 – 2.2) times higher in the group exposed during the first trimester of 
pregnancy as compared to those who were not exposed antidepressants during the first 
trimester of pregnancy. Duration of exposure was not significantly associated with the 
risk of NICU admissions in the first trimester of pregnancy (OR: 0.98 95%CI: 0.76 – 
1.27). 
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Similarly, the odds of NICU admission estimated using marginal structural 
models were 1.6 (95%CI: 1.5 – 1.8) times higher in the group exposed to antidepressants 
in the first trimester as compared to the group that did not receive any antidepressants 
during the first trimester of the pregnancy. Duration of exposure was not significantly 
associated with the risk of preterm term delivery in the first trimester (OR: 1.11 95%CI: 
0.94 – 1.28).  
Table 6 shows the odds of adverse birth outcomes such as preterm delivery, low birth 
weight/small for gestational age and NICU admission associated with prenatal exposure 
to antidepressants during the first trimester of pregnancy.  
Table 4.6 Risk of having adverse birth outcomes among depressed pregnant women 
exposed to antidepressants during first trimester of pregnancy and those who were not 
exposed to any antidepressants during first trimester of their pregnancy 
Risk Associated with Prenatal Exposure to Antidepressants in the First 
Trimester of Pregnancy 
  
Logistics Regression  
OR (95% CI) 
Marginal Structural Model  
OR (95% CI) 
Pre-term Delivery  
1.98 
 (1.2 – 2.1) 
1.8  
(1.5 – 2.1) 
Low Birth Weight/ Small for 
Gestational Age 
1.99  
(1.9 – 2.4) 
1.95 
(1.6 – 2.2) 
NICU Admission  
1.81  
(1.5 – 2.2) 
1.6  
(1.3 – 2.1) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence Interval 
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4.3.4 Prenatal Exposure to Antidepressants in the Second Trimester of Pregnancy and 
Risk of Preterm Delivery 
 
 Analysis conducted using logistic regression showed that the odds of having 
preterm delivery were 1.8 (95%CI: 1.2 – 2.9)  times higher in the group that was exposed 
to antidepressants during the second trimester of pregnancy as compared to those who did 
not receive any antidepressants during the second trimester. Duration of exposure was not 
significantly associated with the risk of preterm term delivery in the second trimester 
(OR: 1.09 95%CI: 0.77 – 1.57). 
Similar results were observed when the analysis was conducted using marginal 
structural models. The odds of having a preterm delivery were 1.6 (95% CI: 1.6 – 1.9)  
times higher in women who received an antidepressant during the second trimester of 
pregnancy as compared to those who did not receive any antidepressants during the 
second trimester of pregnancy. Duration of exposure was not significantly associated 
with the risk of preterm term delivery in the second trimester (OR: 1.12 95%CI: 0.92 – 
1.25).  
4.3.5 Prenatal Exposure to Antidepressants in the Second Trimester of Pregnancy and 
Risk of Low Birth Weight/Small for Gestational Age 
Using logistic regression is was estimated that the probability of having low birth 
weight/small for gestational age infants was 1.8 (95%CI: 1.6 – 2.1) times higher in the 
group exposed to antidepressants during the second trimester of pregnancy as compared 
to those who did not receive an antidepressant during the second trimester of pregnancy. 
Each unit increase in the duration of exposure in the second trimester was associated with 
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1.36 times higher odds of having low birth weight/small for gestational age (95%CI 0.98 
– 1.58), although the association was not statistically significant.  
According to marginal structural models, the odds of having low birth 
weight/small for gestational age were 1.7 (95%CI: 1.6 – 1.9) times higher in the group 
receiving antidepressants during the second trimester of pregnancy as compared to the 
group which did not receive any antidepressant during the second trimester of pregnancy. 
A unit increase in the duration of exposure to antidepressants was not significantly 
associated with the risk of low birth weight/small for gestational age (OR: 1.40 95% CI: 
0.97 – 1.48). 
4.3.6 Prenatal Exposure to Antidepressants in the Second Trimester of Pregnancy and 
Risk of NICU Admission 
According to logistic regression  the risk of NICU admissions was estimated to be 
1.7 (95%CI: 1.3 – 1.9) times higher in the group exposed during the second trimester of 
pregnancy as compared to those who were not exposed antidepressants during the second 
trimester of pregnancy. Duration of exposure was not significantly associated with the 
risk of NICU admissions in the second trimester of pregnancy (OR: 1.24 95%CI: 0.86 – 
1.61). 
Similarly, the odds of NICU admission estimated using marginal structural 
models were 1.7 (95%CI: 1.6 – 1.9) times higher in the group exposed to antidepressants 
in the second trimester as compared to the group that did not receive any antidepressants 
during the second trimester of the pregnancy.  
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Table 7 shows the odds of adverse birth outcomes such as preterm delivery, low 
birth weight/small for gestational age and NICU admission associated with prenatal 
exposure to antidepressants during the second trimester of pregnancy. Duration of 
exposure was not significantly associated with the risk of preterm term delivery in the 
second trimester (OR: 1.31 95%CI: 0.98 – 1.39).    
Table 4.7 Risk of having adverse birth outcomes among depressed pregnant women 
exposed to antidepressants during second trimester of pregnancy and those who were 
not exposed to any antidepressants during second trimester of their pregnancy 
Risk Associated with Prenatal Exposure to Antidepressants in the Second 
Trimester of Pregnancy 
  
Logistics 
Regression  
OR (95% CI) 
Marginal Structural Model  
OR (95% CI) 
Pre-term Delivery  
1.75  
(1.16 – 2.88) 
1.64  
(1.61 – 1.86) 
Low Birth Weight/ Small for 
Gestational Age 
1.76  
(1.55 – 2.10) 
1.73  
(1.61 – 1.86) 
NICU Admission  
1.66  
(1.32 – 1.92) 
1.73  
(1.58 – 1.92) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence Interval 
4.3.7 Prenatal Exposure to Antidepressants in the Third Trimester of Pregnancy and 
Risk of Preterm Delivery  
Analysis conducted using logistic regression showed that the odds of having 
preterm delivery were 1.66 (95%CI: 1.58 – 2.84) times higher in the group that was 
exposed to antidepressants during the third trimester of pregnancy as compared to those 
who did not receive any antidepressants during the third trimester. Duration of exposure 
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was not significantly associated with the risk of preterm term delivery (OR: 1.07 95%CI: 
0.76 – 1.49). 
Similar results were observed when the analysis was conducted using marginal 
structural models. The odds of having a preterm delivery were 1.64 (95% CI: 1.58 – 1.80) 
times higher in women who received an antidepressant during the third trimester of 
pregnancy as compared to those who did not receive any antidepressants during the third 
trimester of pregnancy. Duration of exposure was not significantly associated with the 
risk of preterm term delivery in the third trimester (OR: 1.14 95%CI: 0.95 – 1.35).  
4.3.8 Prenatal Exposure to Antidepressants in the Third Trimester of Pregnancy and 
Risk of Low Birth Weight/Small for Gestational Age 
Using logistic regression is was estimated that the probability of having low birth 
weight/small for gestational age infants was 1.76 (95%CI: 1.32 – 1.99) times higher in 
the group exposed to antidepressants during the third trimester of pregnancy as compared 
to those who did not receive an antidepressant during the third trimester of pregnancy. 
Each unit increase in the duration of exposure in the first trimester was associated with 
1.24 times higher odds of having low birth weight/small for gestational age (95% CI: 
0.78 – 1.37), although the association was not statistically significant.  
According to marginal structural models, the odds of having low birth 
weight/small for gestational age were 1.66 (95%CI: 1.57 – 1.79) times higher in the 
group receiving antidepressants during the third trimester of pregnancy as compared to 
the group which did not receive any antidepressant during the third trimester of 
pregnancy. A unit increase in the duration of exposure to antidepressants was not 
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significantly associated with the risk of low birth weight/small for gestational age (OR: 
1.32 95% CI: 0.99 – 1.27). 
4.3.9 Prenatal Exposure to Antidepressants in the Third Trimester of Pregnancy and 
Risk of NICU Admission 
According to logistic regression  the risk of NICU admissions was estimated to be 
1.59 (95%CI: 1.14 – 2.00) times higher in the group exposed during the third trimester of 
pregnancy as compared to those who were not exposed antidepressants during the third 
trimester of pregnancy. Duration of exposure was not significantly associated with the 
risk of NICU admissions in the third trimester of pregnancy (OR: 1.35 95%CI: 0.87 – 
1.95). 
Similarly, the odds of NICU admission estimated using marginal structural 
models were 1.63 (95% CI: 1.50 – 1.80) times higher in the group exposed to 
antidepressants in the third trimester as compared to the group that did not receive any 
antidepressants during the third trimester of the pregnancy. Duration of exposure was not 
significantly associated with the risk of preterm term delivery in the third trimester (OR: 
1.39 95%CI: 0.96 – 1.45).  
Table 8 shows the odds of adverse birth outcomes such as preterm delivery, low 
birth weight/small for gestational age and NICU admission associated with prenatal 
exposure to antidepressants during the third trimester of pregnancy.  
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Table 4.8 Risk of having adverse birth outcomes among depressed pregnant women 
exposed to antidepressants during third trimester of pregnancy and those who were not 
exposed to any antidepressants during third trimester of their pregnancy 
Risk Associated with Prenatal Exposure to Antidepressants in the Third 
Trimester of Pregnancy 
  
Logistics Regression  
OR (95% CI) 
Marginal Structural Model  
OR (95% CI) 
Pre-term Delivery  
1.66 
(1.58 – 2.84) 
1.64 
(1.58 – 1.80) 
Low Birth Weight/ Small 
for Gestational Age 
1.76 
(1.32 – 1.99) 
1.66 
(1.57 – 1.79) 
NICU Admission  
1.59 
 (1.14 – 2.00) 
1.63  
(1.50 – 1.80) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence Interval 
 
Prenatal exposure to antidepressants was found to be associated with adverse birth 
outcomes such as preterm delivery, low birth weight/small for gestational age, and NICU 
admissions in all the three trimesters. The duration of exposure, that is the number of 
days the antidepressant was prescribed during a semester was not significantly associated 
with the risk of adverse birth outcomes. However, further analysis is required to 
determine the relatively safe time of exposure to antidepressants in order to minimize the 
risk of adverse birth outcomes such as preterm delivery, low birth weight/small for 
gestational age, and NICU admissions.   
4.3.10 Additional Analysis 
 
Additional analysis was conducted using only those women who had been 
prescribed antidepressants in only one trimester of their pregnancy. That is, women who 
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received antidepressants only in Trimester 1 were compared to women who received 
antidepressants only in Trimester 2 and women who received antidepressants only in 
Trimester 3, using women who got antidepressants only in Trimester 1 as the reference 
group. Using logistic regression we found that the risk of having low birth weight/small 
for gestational age was 1.3 (95% CI: 1.09 – 1.45) times higher in the third trimester as 
compared to the first trimester. Also, the risk was 1.2 (95% CI: 1.11 – 1.59) times higher 
in the second trimester as compared to the first trimester. According to marginal 
structural models the risk of low birth weight/small gestational age was 1.42 (95% CI: 
1.38 – 1.54) times higher in the third trimester and 1.31 (95% CI: 1.26 – 1.39) times 
higher in the second trimester as compared to the first trimester.  
Similar results were observed for NICU admissions. Logistic regression showed 
that the risk of NICU admissions were 1.21 (95% CI: 1.07 – 1.61) times higher in the 
third trimester and 1.19 (95% CI: 1.10 – 1.57) times higher in the second trimester as 
compared to the first trimester. Using marginal structural models the risk of NICU 
admission was found to 1.29 (95% CI: 1.20 – 1.37) times higher with exposure in the 
third trimester and 1.25 (95% CI: 1.19 – 1.40) times higher with exposure in the second 
trimester as compared to the first trimester.  
The association of duration was still not statistically significant. The risk of 
adverse birth outcomes was not affected by the number of days antidepressant was 
prescribed in the each trimester.   This additional analysis was not conducted for preterm 
delivery due to the nature of the outcome it would be difficult to accurately estimate the 
exposure.  
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Table 4.9 Comparison of Risk of Low Birth Weight/ Small for Gestational Age and 
NICU Admissions between Trimesters of Exposure to Antidepressants   
Risk of Low Birth Weight/Small for Gestational Age and NICU Admission by 
Trimester of Antidepressant Exposure (Using Trimester 1 as the Referent Group) 
 
Trim
-ester 
1  
Trimester 2 Trimester 3 
Adverse 
Birth 
Outcome 
 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
Logistics 
Regression 
OR (95% CI) 
Marginal 
Structural 
Model OR 
(95% CI) 
Low Birth 
Weight/ 
Small for 
Gestational 
Age 
RG 
1.2 
 (1.11 – 1.59) 
1.31 
 (1.26 – 1.39) 
1.3  
(1.09 – 1.45) 
1.42 
 (1.38 – 1.54) 
NICU 
Admissions 
RG 
1.19  
(1.10 – 1.57) 
1.25 
 (1.19 – 1.40) 
1.21 
 (1.07 – 1.61) 
1.29  
(1.20 – 1.37) 
Note: OR – Odds Ratio; NICU – Neonatal Intensive Care Unit; CI – Confidence 
Interval; RG – Reference Group 
 
4.3.11 Summary 
 
Exposure to antidepressants in all three trimesters was associated with the risk of 
adverse birth outcomes. A separate analysis was conducted for each trimester, where the 
women getting antidepressants in that semester were compared to those who were not 
exposed to antidepressants at any time during their pregnancy. Duration in terms of the 
number of days antidepressants were prescribed during the semester was controlled for as 
a variable in the analysis. Duration of exposure was not associated with the risk of 
adverse birth outcomes.  
Conducting additional analysis using women who were prescribed antidepressants 
only in one trimester of their pregnancy and first trimester was sued as the referent group. 
We found that the risk of low birth weight/small for gestational age and NICU 
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admissions was higher with exposure in the third and second trimester as compared to the 
first trimester.  
4.4 SUMMARY  
 
Through both the methods of analysis we found that the risk of adverse birth 
outcomes such as preterm delivery, low birth weight/small for gestational age and NICU 
admissions were higher in the exposed group as compared to the unexposed group. The 
odds of having an adverse birth outcome ranged from 1.45 (95%CI: 1.28 – 2.26) to 1.72 
(95%CI: 1.63 – 1.79).  
All classes of antidepressants that SSRIs, Atypicals, SNRIs, and TCAs when 
compared to the unexposed group, were found to be associated with a higher risk of 
adverse birth outcomes. Both logistic regression and marginal structural models yielded 
similar results. Upon comparing the different classes of antidepressants to SSRIs we 
found that the risk of adverse birth outcomes was not significantly different between the 
different types of antidepressants. Only TCAs had a statistically lower risk of NICU 
admissions as compared to SSRIs. Using marginal structural models we found that the 
risk of NICU admissions was 0.85 times (95% CI: 0.65 – 0.97) lower in TCAs as 
compared to SSRIs. These results are can attributed to a variety of reasons, TCA were 
prescribed to relatively fewer people as compared to the other antidepressants. Also, 
TCAs prescription has reduced over the past decade and is mostly prescribed to older 
women.  
Exposure to antidepressants in all three trimesters was associated with the risk of 
adverse birth outcomes. Although the duration of exposure that is the number of days for 
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which the antidepressant was prescribed in each trimester was not associated with the risk 
of adverse birth outcomes. Conducting additional analysis we found that the risk of low 
birth weight/small for gestational age and NICU admissions was higher with exposure in 
the third and second trimester as compared to the first trimester.  
Delineating the effect of antidepressants from depression using marginal 
structural models showed a stronger association and had narrower confidence intervals as 
compared to logistic regression.     
4.5 REFERENCES 
1. Labbe D, Rytz A, Brunstrom JM, Forde CG, Martin N. Influence of BMI and 
dietary restraint on self-selected portions of prepared meals in US women. 
Appetite. 2016 Nov 8. pii: S0195-6663(16)30694-8. 
2. Freedman DS, Zemel BS, Ogden CL. Secular trends for skinfolds differ from 
those for BMI and waist circumference among adults examined in NHANES from 
1988-1994 through 2009-2010. Am J Clin Nutr. 2016 Nov 2. pii: ajcn135574. 
[Epub ahead of print] PubMed PMID: 27806976. 
3. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among 
adults and youth: United States, 2011–2014. NCHS data brief. 2015 Nov; 
219(219):1-8. 
4. https://www.cdc.gov/pcd/issues/2014/13_0415.htm Accessed November 10, 2016 
5. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes 
mellitus in the United States, Pregnancy Risk Assessment Monitoring System 
(PRAMS), 2007-2010. Prev Chronic Dis. 2014 Jun 19;11:E104. 
 105 
 
6. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes 
mellitus in the United States, Pregnancy Risk Assessment Monitoring System 
(PRAMS), 2007-2010. Prev Chronic Dis. 2014 Jun 19;11:E104. 
7. American College of Obstetricians and Gynecologists.; Task Force on 
Hypertension in Pregnancy.. Hypertension in pregnancy. Report of the American 
College of Obstetricians and Gynecologists’ Task Force on Hypertension in 
Pregnancy. Obstet Gynecol. 2013 Nov;122(5):1122-31. 
8. http://www.cdc.gov/nchs/data/databriefs/db220.htm Accessed November 10, 
2016 
9. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L. 
Changes in diabetes-related complications in the United States, 1990-2010. N 
Engl J Med. 2014 Apr 17;370(16):1514-23. 
10. https://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf 
Accessed November 10, 2016 
11. Wu J, Davis-Ajami ML, Keiser S, Sykes L. Antidepressant Prescription 
Medication Use Patterns among Insured, Low Income Pregnant Women. 
American Journal of Public Health Research. 2013 Jan 23;1(3):72-7. 
12. Huybrechts KF, Palmsten K, Mogun H, Kowal M, Avorn J, Setoguchi-Iwata S, 
Hernández-Díaz S. National trends in antidepressant medication treatment among 
publicly insured pregnant women. General hospital psychiatry. 2013 Jun 
30;35(3):265-71. 
 106 
 
CHAPTER 5 
DISCUSSION 
 
Depression is a growing concern to healthcare professionals. It is a mental illness 
that can be debilitating to patients, and is costly and challenging to treat. Women are 70% 
more likely to suffer depression than men
1
.  Depression has become a common problem 
during and after pregnancy. Prevalence of depressive disorders in pregnant women ranges 
from 14% to 23%
2-4
. Both depression and antidepressants have been associated with 
adverse birth outcomes such as preterm delivery
5-12
, low birth weight/small for 
gestational age
5-12
 and NICU admissions
5,10-13
. Over the past decade the proportion of 
pregnancies with antidepressant use has increased from 5.7% of pregnancies to 13.4% of 
pregnancies and is projected to increase further
1-2,14
. A similar trend was seen in our 
study; prescription of antidepressants increased from 8.7% in 2008 to 20.8% in 2014. 
Over the past decade several studies have assessed the association between prenatal 
exposure to antidepressants and adverse birth outcomes, although the results have been 
inconsistent
15-24
.   These will be discussed below, and will provide context to the results 
of the current study. 
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5.1 IMPACT OF PRENATAL EXPOSURE TO ANTIDEPRESSANTS ON RISK 
OF PRETERM DELIVERY 
Several studies examine the incidence of preterm birth in women exposed to 
antidepressants during pregnancy
18, 25-32
. These include meta-analysis
25
, prospective 
cohort studies
26,27,30
, retrospective cohort studies
28-29,31
, and case control studies
32,18
. 
Some studies examined mean gestational age (rather than preterm delivery)
30
. In the 
majority of studies, including the current study, prevalence of preterm delivery was 
considered
28-29,31-32
.  In our study we found that prenatal exposure to antidepressants is 
significantly associated with an increased risk of preterm delivery. Similar results were 
seen in a meta-analysis of nine studies that showed a significant increase in preterm births 
with an OR 2.23 (95%CI 1.61 – 2.6)18. Several cohort studies which considered different 
classes of antidepressants (SSRIs, Atypical, TCA and SNRI) demonstrated a statistically 
significant increase in preterm delivery rates for all classes
21-25, 34-36
. In our study we drew 
a similar conclusion, all the classes of antidepressants considered were significantly 
associated with increased odds of preterm delivery. However, no other study estimated 
the relative odds of different classes of antidepressants compared to one another. Two of 
the afore mentioned studies showed a relationship between preterm delivery rates and late 
exposure
24,34
. However in our study we did not find a statistically significant difference in 
the risk of preterm delivery and trimester of exposure to antidepressants. A prospective 
cohort study conducted revealed a correlation between preterm birth and chronic 
exposure to antidepressants but not with short term exposure 
37
. In our study we found 
that duration of exposure was not significant, any exposure to antidepressants during 
pregnancy was found to be associated with an increased risk of preterm delivery. Some 
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studies also demonstrated a positive finding between duration of exposure and preterm 
birth
34-36
. All of these studies have similar weaknesses, with no measures of actual drug 
exposure or controls for confounders such as smoking and, in particular, the effects of 
underlying depression. Some of the more rigorous studies have tried to tease out the role 
of untreated maternal depression. In a study of 119, 547 prescription records matched 
with hospital separation records, the authors found that SSRI-exposed babies had a higher 
rate of preterm birth than babies exposed to depression alone (p > 0.01)
29
. Similarly, 
another small prospective study compared women with depression alone and treatment 
with SSRIs and found a statistically significant higher preterm birth rate in the exposed 
infants (14% exposed group, 0% depressed group)
38
. In contrast, another small study did 
not detect any difference between treated and depressed groups
31
. However, in our study 
we found that the odds of having preterm delivery were significantly higher in depressed 
women who had a prescription antidepressant during pregnancy as compared to those 
who did not. Also, our study had the advantage of having a large sample size and detailed 
drug information.  
 
5.2 IMPACT OF PRENATAL EXPOSURE TO ANTIDEPRESSANTS ON RISK 
OF BEING LOW BIRTH WEIGHT/SMALL FOR GESTATIONAL AGE 
 
Similar to preterm delivery, a number of studies have examined the impact of 
prenatal exposure to antidepressants on low birth weight and small for gestational age. A 
meta-analysis showed a statistically significant risk of low birth weight for gestational 
age
18
. Similar results were seen in our analysis, where we report that prenatal exposure to 
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antidepressants was associated with an increased odds of low birth weight/small for 
gestational age. Several other cohort studies had similar results
26,28,29,33,39-41
; and several 
others had conflicting results
15,18,24,30,34,43-44
. In one study, authors attempted to increase 
the sensitivity of the study by using propensity scoring to control for confounders and 
found an effect on birth weight related to exposure
35
. Only two studies controlled for 
confounders such as depression, smoking, maternal age or maternal weight, and these 
showed no differences in birth weight in babies born to exposed or non-exposed 
mothers
44-45
. These studies were limited by their sample size. An increased possible risk 
of large birth weights following TCA treatment was reported in one study
34
. Although 
partially related to higher body mass index in mothers taking antidepressants, the effect 
did not completely disappear when this was controlled for. However these studies did not 
control for drug class and duration of antidepressant prescribed. 
It needs to be acknowledged here that low birth weight and small for gestational 
age are not ideal measures for intrauterine growth; however, these are the two most 
commonly used measures in the literature and are generally considered together
36-39
. 
Studies show that the low birth weight is strongly associated with pre-term delivery; the 
magnitude and direction of misclassification of low birth weight differed by preterm and 
full term birth
40-41
. Small for gestational age has been considered to be relatively more 
accurate than low birth weight as the weight of infants of the same gestational age is 
compared
40
. In our study population there were 709 infants having low birth weight and 
687 were small for gestational age. A total of 649 infants were diagnosed with both low 
birth weight and being small for gestational age.  
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5.3 IMPACT OF PRENATAL EXPOSURE TO ANTIDEPRESSANTS ON RISK 
OF NICU ADMISSIONS 
Relatively fewer studies have examined the association between admission to 
NICU and prenatal exposure to antidepressants
31,36,39,43-44
. Most of the studies show some 
association between prenatal exposure to antidepressants and neonatal adaptation 
difficulties which can be measured in various ways, from gross markers such as NICU 
admission to more subtle evaluations such as behavioral observations.  This variability in 
outcome measure makes it difficult to draw general conclusions. Large database or 
registry studies have variously suggested a 1.5 times increased risk of NICU admission 
with third trimester exposure compared to first trimester exposure 
47
. However in our 
study we found exposure to antidepressants during pregnancy, irrespective of trimester, is 
associated with increased odds of having NICU admission. Similar to our results, a meta-
analysis
48
 of prospective controlled trials included consideration of 1066 mother – infant 
pairs and found a three-fold increased risk of SCN/NICU admission following 
antidepressant exposure. However, none of the studies in the meta-analysis included a 
depressed, non-drug-treated group. Two subsequent studies do include such a group. A 
study conducted in 132 infants found that exposure to citalopram during pregnancy had a 
four-fold increased incidence of NICU admission compared to matched infants exposed 
to untreated maternal depression or controls
30
. Two other controlled studies did not find 
an association between SSRIs exposure and NICU admission, however, these studies 
were limited by sample size and were prone to recall bias as information was collected 
through an interview with the mothers. Studies examining the impact of prenatal 
exposure to TCAs are limited to case reports and case series. Several case reports 
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describe an association between prenatal exposures to clomipramine
49-50
 and 
imipramine
51-52
 with NICU admissions. With regard to the newer antidepressants, 
evidence is scant. Some of the studies include venlafaxine exposure
53-56
 and suggest a 
similar rate of NICU admissions as that associated with SSRIs. However, none of the 
studies control for duration and time of exposure and do not estimate the relative impact 
of the different types of antidepressants.  
5.4 ADDRESSING THE GAPS IN THE LITERATURE  
In our study, we found that the prenatal exposure to antidepressants is associated 
with higher odds of having an adverse birth outcome such as preterm delivery, low birth 
weight/small for gestational age, NICU admissions. This association was not affected by 
the type of antidepressant prescribed or the trimester of exposure. Our study results are 
consistent with several studies in the existing literature
26,28,29,33,39-41
, but are conflicting 
with several others
8-11,15,18,24,30,34,43-44
. The current literature on the impact of prenatal 
exposure to antidepressants on adverse birth outcomes has inconsistent results. There are 
several possible reasons for these inconsistencies. First, studies have used a variety of 
different methodologies
18,57-59
, which make them difficult to compare. Second, many 
studies lack an appropriate control, which introduces many threats to internal validity
18,57-
59
. Third, most of the studies look only at prenatal exposure to selective serotonin 
reuptake inhibitors (SSRIs); there is limited information available on other classes of 
antidepressants
18,57-59
. Fourth a number of studies have failed to control for confounders 
such as maternal smoking, parity, and duration of exposure to antidepressants and most 
importantly maternal depression
18,57-59
. Through our study we have tried to address these 
gaps in the literature in the following ways:  
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5.4.1 Controlling for Maternal Depression 
Studies show that maternal depression can have an impact on the pregnancy and 
fetus
15
. Untreated depression has been found to be associated with preterm delivery, low 
birth weight and small for gestational age
15-17
.We controlled for maternal depression in 
our study. The information on maternal depression was obtained from the SC Medicaid 
claims database using the ICD 9 diagnosis. In addition we have used marginal structural 
models to delineate the effect of antidepressants from the effect of depression itself on the 
adverse birth outcomes
62-63
.  
5.4.2. Larger Focus on SSRIs 
Since SSRIs are the most commonly prescribed antidepressants, a majority of the 
studies focus on the impact of prenatal exposure to SSRIs alone on adverse birth 
outcomes. Although there is still information available about the impact of prenatal 
exposure to TCAs, the information related to Atypical and SNRIs is scant. In our study 
we have examined the association of prenatal exposure to all the classes of 
antidepressants that SSRIs, Atypical, SNRIs, and TCAs. We also did a comparative 
analysis using SSRIs as the reference group to estimate relative safety of the 
antidepressants.  We found that there is no statistically significant difference in risk of 
adverse birth outcomes across the multiple drug classes, compared to SSRIs. 
5.4.3. Inadequate Controlling for Confounders 
Several of the studies examining the impact of prenatal exposure to 
antidepressants on adverse birth outcomes fail to control for confounders such as 
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smoking status, mother’s BMI, gestational diabetes, gestation hypertension, duration and 
trimester of exposure to antidepressants etc. In our study we controlled for all of these 
confounders. Through the linkage of SC Medicaid claims data with birth certificates we 
were able to access important information such as mother’s smoking status before and 
during pregnancy, gestational diabetes, gestational hypertensions, mother’s BMI, level of 
prenatal care, and history of poor birth outcomes. In addition to this we also had detailed 
information regarding the antidepressants prescribed which helped us control for duration 
and trimester of exposure.   
5.4.4. Observational Studies/Establishing a Causal Relationship 
  All the studies conducted to examine the association between prenatal exposure to 
antidepressants and risk of adverse birth outcomes have been observational. Several 
standard methods have been used in this setting to estimate the association between 
prenatal exposure to antidepressants and the risk of adverse birth outcomes. However, 
none of the methods can be used to establish causality. Ideally a randomized controlled 
trial would be conducted to establish a causal association. Due to ethical concerns we 
cannot randomize treatment in this study population. Hence we used marginal structural 
models, a relatively new technique that has not been used in the field of reproductive 
epidemiology
63-64
. In MSM, we used counterfactuals to create a pseudo population that is 
similar to our actual study population
62
. Using this pseudo population we were able to 
statistically mimic a randomized control trial
62-66
.  
The result from the two analysis were in the same direction; both logistic 
regression and marginal structural models estimated an increase in the risk of adverse 
birth outcomes. When conducting analysis using logistic regression the odds of having 
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preterm delivery were 1.58 (95%CI: 1.19 – 2.10) times higher in the study participants 
that received an antidepressant during pregnancy as compared to those who did not 
receive any antidepressants at any time during the pregnancy. Whereas, according to the 
analysis conducted using marginal structural models, the odds of preterm delivery were 
1.72 times (95% CI: 1.63 – 1.79) in the group that received antidepressants during 
pregnancy as compared to the group that did not receive an antidepressant during 
pregnancy. Similar results were observed for low birth weight/small for gestational age 
and prevalence of NICU admissions. Using logistic regression it was estimated that 
antidepressant use during pregnancy was associated with higher odds of the infant having 
low birth weight/being small for gestational age,  OR = 1.57 (95% CI: 1.42 – 2.76) and/or 
NICU admissions, OR: 1.45 (95%CI 1.28 – 2.26). Marginal structural models showed 
that the prenatal exposure to antidepressants increased the odd of having low birth 
weight/small for gestational age 1.63 times (95%CI: 1.53 – 1.73) and the odds of having 
a NICU admission by 1.66 times (95% CI: 1.58 – 1.73).   
Marginal structural models gives a stronger association. This is possibly due to 
the fact that they control for maternal depression more effectively providing with the 
effect of antidepressants alone on the risk of adverse birth outcomes. Also, marginal 
structural models provide us tighter confidence intervals. Marginal structural models and 
logistic regression both suggest that prenatal exposure to antidepressants is associated 
with an increased risk of adverse birth outcomes. The weights used in marginal structural 
models can be interpreted as the number of copies of each observation that are necessary 
to form a pseudo-population in which use antidepressants is confounded. Hence, the 
results are more robust with narrower confidence intervals.  
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5.5 CONCLUSION 
In our study we examined the impact of prenatal exposure to antidepressants on 
adverse birth outcomes such as preterm delivery, low birth weight/small for gestational 
age and NICU Admissions. We conducted the analysis using two different statistical 
techniques. First logistic regression, as this is the most commonly used technique and 
would help us make our results more comparable. Second, we used marginal structural 
models, a relatively new method which helped us delineate the effect of antidepressants 
from the effect of depression. Marginal structural models also helped us to mimic a 
randomized control trial statistically which cannot be conducted practically in this 
scenario. Using both analyses we found that prenatal exposure to antidepressant is 
significantly associated with an increase in the odds of having adverse birth outcomes 
such as preterm delivery, low birth weight/small for gestational age, and NICU 
admissions. The odds ratio ranged from 1.58-1.99 and were all statistically significant. 
Further we did a comparative analysis between the different types of antidepressants 
using SSRIs as the reference group. We found that all antidepressants are associated with 
the risk of adverse birth outcome, there is no difference in the measure of risk among the 
various classes of antidepressants compared to the referent category, SSRI. We also 
found that the duration and trimester of exposure to antidepressant did not significantly 
impact the risk of adverse birth outcomes.  
We addressed some of the key concerns in the existing literature through our 
study. We not only controlled for maternal depression which is an important confounder 
but we were also able to control for confounders such as maternal smoking, maternal 
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BMI, parity, risk of previous adverse birth outcomes etc. We also did an analysis to 
compare the relative risk of the class of antidepressants on the risk of adverse birth 
outcome by using SSRIs as the referent group. This analysis gave more insight into the 
other classes of antidepressants and also attempted to establish their relative safety. We 
used to separate analytical tools for this study. We used the traditional logistic regression 
to ensure that our study is comparable to other studies in the current literature. We also 
used the relatively new marginal structural models to statistically mimic a randomized 
controlled trial from observational data. In conclusion we found that prenatal exposure to 
antidepressants is significantly associated with a higher risk of adverse birth outcomes 
such as preterm delivery, low birth weight/small for gestational age, and NICU 
admissions, irrespective of the type of antidepressant prescribed and duration and 
trimester of exposure.  
5.5.1 Strengths  
The strengths of our study are:  
1. This study was conducted using a merged dataset from South Carolina Medicaid 
and South Carolina Registry of Births which is a database of all birth certificates 
issued in the state of South Carolina. This provided us a rich data which captured 
a number of important confounders such as prenatal care, mother’s education, 
mother’s weight, uterine bleeding etc. as well as risk factors such as maternal 
smoking, alcohol use, gestational diabetes, gestational hypertension etc.  
2. The merged dataset also allowed us to control for behavioral  confounders such 
as, maternal smoking, maternal alcohol use, maternal race, maternal and paternal 
occupation, conditions during the pregnancy (ex. gestational hypertension, 
 117 
 
anemia, eclampsia, gestational diabetes, uterine bleeding), birth abnormalities or 
anomalies (ex. cleft palate, heart malformations), multiple births, etc. Data from 
the birth certificates gave us information regarding the birth outcomes such as 
pre-term delivery, low birth weight/small for gestational age, and NICU 
admissions which helped us identify the cases accurately. 
3. This study has attempted to explore the causal association between prenatal 
exposure to antidepressants and risk of adverse birth outcomes using MSM within 
an observational data set.  
4. The South Carolina Medicaid finances about 50% of total births in state. This 
gave us a large enough sample size to facilitate detailed subgroup analysis and 
confidently extrapolate our findings to this population results.  
5. South Carolina Medicaid has a strong representation of vulnerable populations 
including racial/ethnic minorities generally representative of the state population. 
Race and ethnicity are recorded in this database, in contrast to many commercial 
databases. The South Carolina Medicaid population is relatively homogeneous 
with respect to the socio-economic status.  
6. South Carolina Medicaid Claims database can be merged with the birth 
certificates which contained information on confounders such as mother’s BMI, 
parity, smoking status etc. Maternal obesity, smoking during pregnancy and parity 
have been found to significantly associate with the risk of adverse birth outcomes. 
Having information on these confounders allowed us to control for them in our 
analysis.  
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5.5.2 Limitations  
Some of the limitations of our study are:  
1. The study was conducted using the South Carolina Medicaid database which 
limits generalizability for the results to other states. 
2. Depression is often associated with other psychiatric illnesses, in this study we 
did not control for other psychiatric disorders or prescription of antipsychotic 
medicines.  
3. Only the month and year of delivery/birth date was given in the Medicaid 
database hence for the ease analysis we used the 15 of each month as the date. As 
a result the date of conception and trimester dates might not be accurate.  
4. There is a potential of considerable misclassification arising from the use of low 
birth weight as an outcome. Low birth weight is associated with preterm birth, so 
the magnitude and direction of misclassification will differ by preterm and full 
term birth. Also, small for gestational age may not be a perfect measure for 
intrauterine growth. As the estimated gestational age might not be accurate.  
5. Since this is an observational study, we cannot draw a causal inference of 
association. Although MSM helps statistically mimic a randomized control trial, 
there might be some unobserved confounders that we could not control for. 
6. The causal inference from our MSM depends on two key assumptions  
a. We assumed that the covariates in maternal depression are sufficient to 
adjust for both confounding and selection bias due to loss to follow-up.  
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b. We assumed that our MSM for the effect of antidepressants on adverse 
birth outcomes is correctly specified. In an observational study, these 
assumptions cannot be tested.  
5.5.3. Future Research Recommendations 
Current research shows that antidepressant use in pregnancy is well studied and 
gives sufficient evidence to state that the treatment of pregnant women with 
antidepressants is a challenging and complex task for the healthcare providers.  In our 
study we have tried to establish a causal association between prenatal exposure to 
antidepressants and adverse birth outcomes, further research in the field is needed. 
Studies have not yet adequately controlled for factors that can adversely affect pregnancy 
and birth outcomes, such as other maternal illness or adverse health behaviors (e.g., 
alcohol consumption, recreational drugs, etc.). Hence there is a need for more focused 
studies that take into account these important factors, as they may influence the 
association between antidepressant exposure and adverse birth outcomes. There is a need 
to study the duration of exposure with more precision, while taking into account the 
patient’s adherence to the prescribed medications. Also there is a need to examine and 
clarify a dose response relationship between the prenatal exposure to antidepressants and 
risk of adverse birth outcomes, if such a relationship exists This would help clinicians 
know the threshold dose they can use to treat cases that absolutely require 
pharmacotherapy to control depression. Another recommendation would be to include 
more recently approved antidepressants. Lastly, there is a need for a more inclusive 
definition of exposure which measure the dose, duration, trimester of exposure, and the 
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gaps in therapy.  Such a definition would allow a more comprehensive measure of the 
construct, resulting in more precise results and conclusions.  
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APPENDIX A: CORRELATION MATRIX OF THE VARIABLES INCLUDED IN THE ANALYSIS 
Table A1 Correlation Matrix of the Variables Included in the Analysis 
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Mother's Age 
(Years)  1.00 
          Mother's Weight  0.27 1.00 
         Mother's 
Education -0.13 0.05 1.00 
        Prenatal Care 
(Kotelchuck 
Index) 0.20 0.11 0.16 1.00 
       Smoking Status -0.13 0.04 -0.06 0.12 1.00 
      Parity 0.22 0.57 0.25 0.08 0.40 1.00 
     Number of Risk 
Factors  0.52 -0.63 0.31 0.62 0.24 0.24 1.00 
    Infant Sex 0.23 0.15 0.03 0.00 -0.64 0.10 -0.36 1.00 
   Mother’s Race   -0.45 0.31 -0.07 -0.01 0.59 0.12 0.32 0.34 1.00 
  Year of Birth 0.60 -0.44 0.12 0.02 0.55 0.14 0.29 0.33 0.22 1.00 
 Antidepressant 
Use  -0.67 0.52 0.17 0.04 -0.50 0.16 -0.26 0.32 -0.23 -0.28 1.00 
 
 
